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Welcome 
 
The Facet Injection Study team are delighted that you have agreed to join this consensus conference and 
would like to welcome you. Your expert contribution to the development of consensus is very important for 
the success of this research. This document introduces you to the research and the five key areas on which 
we seek consensus, in addition to the evidence we have collated to support the consensus process. We hope 
you will have the opportunity to read this document before the conference. You may find it helpful to start 
by reading the one page summaries of each section. 
 
I will be facilitating the consensus conference. I am a Medical Sociologist with clinical experience in General 
Medical Practice and has facilitated similar consensus events. I am not a specialist in back pain or clinical 
trials. If you have any questions about the consensus process please feel free to contact me using the details 
below.  
Frances Griffiths 
Professor of Medicine in Society 
f.e.griffiths@warwick.ac.uk 
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2 Introduction 
 
Low back pain is a common and costly disorder. Facet joints are paired structures between spinal vertebrae 
that allow flexion, and some rotation, of the spine. Facet joint disease can be a cause of low back pain. 
Although widely used, the available evidence does not support the use of facet joint injections as treatment 
for low back pain; National Institute for Health and Care Excellence (NICE) advised against their use in 2009. 
This consensus conference will inform the design of a randomised feasibility study to look at the effectiveness 
of adding facet joint injections to a 'best usual care' package of physiotherapy treatment developed 
specifically for this trial.  
 
The study will be conducted in 2 phases.  
 
Phase 1 is an exploratory phase involving systematic reviews and this consensus process, to develop and 
evaluate agreed criteria  
 For identifying people with suspected facet joint pain 
 To develop a protocol for the injection of facet joints in an agreed consistent manner 
 To develop and evaluate a standardised control treatment deliverable in the NHS and congruent with 
NICE guidance ('best usual care') 
 To develop and test systems for collecting short and long term pain outcomes, including measures 
required for economic evaluation.  
 
The outcomes of the exploratory phase which affect the conduct of the proposed randomised pilot trial, 
phase 2, will be addressed via a substantial amendment to the protocol. The phase 2, randomised feasibility 
trial will run in four NHS Acute Trusts. Patients referred for treatment of low back pain present for at least 
six months, after failure of conservative treatment, will be considered as potential participants, with a total 
of 150 participants to be recruited. Participants eligible for the study whom provide written informed consent 
will be randomised to receive either facet joint injection with 'best usual care' package of physiotherapy 
treatment, or 'best usual care' package of physiotherapy treatment only. The injection is a mixture of a 
steroid and a local anaesthetic injected into up to six facet joints. Injections will be performed under X-ray 
control by a trained clinician. Participants will be included in the study for a period of 12 months. Short term 
effects on pain will be collected using text messaging (initially daily), paper diary also available, for up to three 
months, with postal questionnaire follow up at three, six and 12 months. 
 
Previous trials of facet joint injections do not constitute a robust evidence base to inform decisions about the 
use of facet joint injections. The NIHR HTA Commissioning Board noted the need for such a trial as a high 
priority to the NHS. The Board called for proposals for a trial to test the use of facet joint injections as 
treatment for non-specific low back pain, i.e. lower back pain for which no serious medical cause (malignancy, 
infection, fracture) has been identified, with pain present for at least six months. The National Institute for 
Health Research Health Technology Assessment (NIHR HTA) Commissioning Board has funded two studies of 
which this is one. We will explore the feasibility of running a randomised controlled trial to test the hypothesis 
that, for people with suspected facet joint pain contributing to persistent non-specific low back pain, adding 
the option of facet joint injections, with local anaesthetic and corticosteroids, to best usual non-invasive care 
available from the NHS is clinically and cost-effective. 
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2.1 Aim of the consensus conference 
The aim of this conference is to draw on evidence and expertise to reach a consensus on questions that will 
affect the details of trial design. The consensus results will be written up as a document for use by the trial 
team and for publication. The names of all those attending the consensus conference will be published with 
the consensus document. At the end of the consensus conference there will be an opportunity for individuals 
to write a signed statement detailing any disagreement and this will be published along with the consensus 
document. 
 
3 NIHR HTA brief 
 
Below is the text of the NIHR HTA brief for the commissioned projects. 
 
1 Intervention / Technology: Facet-joint injections – applicants should indicate, and justify, the procedure to 
be used and what will be injected.  
 
2 Patient group / Target group: Patients with back pain of at least six months duration that has not improved 
after treatment in accordance with NICE guidance: the treating clinician would now consider the use of facet 
joint injection. Applicants should define the patient group to be assessed for inclusion, and describe in detail 
criteria for entry into the trial (i.e. how will those with facet joint pain be identified).  
 
3 Setting: Secondary care clinics (e.g. pain or orthopaedic), possibly also primary care  
 
4 Control or comparator: (i) Usual care, as defined by NICE guidelines, (ii) sham facet joint injection (method 
of delivering the sham procedure to be investigated in the feasibility phase) 
 
5 Study Design: A feasibility study to i) assess the ability to recruit both centres and patients, and to deliver 
the intervention; ii) develop a plausible sham procedure; iii) develop criteria for assessment for, and diagnosis 
of facet joint pain, iv) decide on most appropriate procedure for facet joint injection; v) develop a proposal 
for a definitive study. The definitive study should be a three arm trial comparing (i) facet joint injection with 
injection of active agents, (ii) sham facet joint injection, method of delivering the sham procedure to be 
investigated in the feasibility phase, and (iii) usual care in accordance with NICE guidance.  
 
6 Important outcomes: Ability to recruit trial centres and patients; agreed sham and active  intervention 
packages, ability to randomise patients; identification of possible subgroups for further investigation in a 
definitive trial; proposal and protocol for a definitive trial. Applicants should also indicate what outcomes 
they consider might be used for a definitive study (e.g. pain, mobility, quality of life) and how the feasibility 
study might further inform their choice.  
 
Two studies were commissioned to assess the clinical- and cost-effectiveness of facet-joint injections in 
selected patients with non-specific low back pain. The competing project is comparing facet joint injections 
with local anaesthetic and steroid to a sham procedure in people with positive diagnostic test for facet joint 
disease. (Competing project reference link http://www.controlled-trials.com/ISRCTN12191542/12191542). 
 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  8 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
4 Five Key Questions: Reviewing the Evidence 
 
The questions to be considered at this consensus conference are key to trial design and of vital importance 
for the production of robust evidence on facet joint injection. During the consensus conference we will be 
considering five questions. In sections 5 to 10 below we set out the evidence available to help us answer 
these questions. This evidence has been collected and analysed systematically as described in each section. 
During the consensus conference small groups will consider each of these five questions and reach a 
consensus using the Nominal Group Technique. In a plenary any discrepancies between the small groups will 
be discussed to achieve final consensus. This process will be explained at the start of the consensus 
conference. 
For each question we have written a summary of what the evidence suggests and the implications for the 
study of the answer to the question. Following the summary we present details of the systematic review. 
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5 Identifying patients with suspected facet joint pain 
5.1 Summary 
 
Question: What is the best choice of clinical assessment to identify patients with suspected facet joint pain? 
 
What the evidence suggests 
The empirical evidence to date remains limited as to how best to clinically ‘diagnose’ lumbar facet joints as a 
source of pain in chronic low back pain patients.  Whilst certain signs/symptoms or aggravating factors have 
been suggested to be indicative of facet joint pain, there use is generally not supported by the research 
evidence.  The one technique/test that may offer some validity in terms of non-invasive diagnosis is a regular 
compression pattern when testing combined movements.  However, the research to date is small scale and 
provisional. 
 
Implication for the study 
The ability to identify patients where the facet joints are a suspected source of pain is important as it is one 
of the entry criteria for enrolment in the study.  Being able to accurately identify a relatively homogenous 
group of back pain patients with facet joint pain will allow a true evaluation of the potential benefits of facet 
joint injections.   
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5.2 Background  
 
Between 5-15% of people with chronic low back pain (LBP) are believed to have disease of one or more facet 
or zygoapophyseal joints contributing to their pain yet there is considerable uncertainty on how to identify 
such people. We needed to evaluate and update the evidence-base for non-invasive assessment techniques 
available to indicate suspected facet joint pain.  
 
Numerous non-invasive tests are available to clinicians to help ‘diagnose’ pain that may arise from the facet 
joints.  Revel et al (1998)1  considered facet joint pain to be typified by age >65, pain well relieved by 
recumbency and an absence of pain exacerbation by coughing, forward flexion, rising from flexion, hyper 
extension or extension–rotation.  Conversely, Wilde et al (2007)2, reporting expert consensus, advocated 
exacerbation of pain on extension, lateral side flexion or rotation to the ipsilateral side with including pain 
unilateral in nature, lacking radicular features, and reduction in local passive movement or stiffness at the 
suspected site.     
A commonly used, well established physiotherapy testing procedure of ‘combined movements’ purports to 
load the facet joint.3, 4  This procedure simply combines different spinal movements to produce either a 
regular or irregular compression pattern and may offer some utility in directing specific back pain treatment 
options.5 
The most recent systematic review evaluating tests to identify the facet joint as a source of low back pain6, 
identified no evidence to support any specific test.  A subsequent update (to January 2012) identified no 
additional published evidence.    
 
5.3 Methods  
 
The review updated an existing systematic review and reports the evidence for non-invasive physical 
examination techniques available to indicate suspected facet joint pain.6  The evidence synthesis comprises 
of two components; 
1. Systematic review (SR) of the empirical, published evidence (2007 to present) 
2. Narrative evidence synthesis from seminal texts of physical therapy 
 
Questions:  
1. What is the diagnostic validity/accuracy (sensitivity, specificity, positive predictive values and 
negative predictive values) of physical examination techniques/tests available to clinicians to identify 
the facet joint as the source of low back pain? 
 
2. What are the common components utilised in a clinical examination for facet joint pain e.g. pain 
referral maps or patterns, palpation, observation of posture and range of motion testing?  
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Selection of studies 
Criteria for inclusion of studies; 
1. Population  
Participants had low back pain and no known or suspected serious pathology  
 
2. Appropriate reference test  
An appropriate reference test based on those of the International Association for the Study of Pain, 
(intra-articular blocks or medial branch blocks) 
 
3. Index test 
Evaluate at least one index test available to clinicians e.g. include pain referral patterns or pain 
maps, active range of motion, palpation (static and active), Passive Physiological Inter-vertebral 
Movements (PPIVM) and Passive Accessory Inter-vertebral Movements (PAIVM). 
 
4. Diagnostic validity  
Studies should contain a 2x2 contingency table or data enabling the development of one must be 
present  
The outcome of interest for the SR was pain or function with an appropriate reference e.g. intra-articular 
facet or medial branch blocks.  
MEDLINE, EMBASE, CINAHL, Allied and Contemporary Medicine Database (AMED) and BIOSIS were searched 
in addition to the grey literature databases and citation tracking / hand searching as appropriate. 
Search terms  
Low back pain OR back pain OR lumbar vertebrae OR spine OR spinal diseases OR facet* OR facet joint* OR 
zygapophyseal joint* OR lumbar sacral pain.  Intervention search terms included orthopaedic OR manual OR 
physical OR therapeutic exercise OR exercise therapy OR rehabilitation OR physiotherapy  
 
Exclusion or inclusion criteria 
Pragmatically, all study types were considered initially then included or excluded in the first stage of 
selection.  Full text article were reviewed and relevant quality assessment undertaken. 
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5.4 Results 
 
Database searches identified 2061 hits; one of which was relevant to our question.7 Further hand searching 
identified one abstract directly related to our question and the author was approached to share initial data 
with the FIS team and agreed. 8  Key themes from seminal texts in osteopathy and physiotherapy are 
summarised. 
 
 
 
 
 
 
 
 
 
 
Review Process: Diagnosis 
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Reference Setting Study Population Diagnostic test Findings 
Challinor, et al 
20138 
Secondary care  
 
Patients undergoing 
diagnostic lumbar 
medial branch block 
(MBB)  
N=96 (61 F: 35 M) 
Median age 63.5 yrs  
Median LBP 6 yrs (IQR 12) 
 
Combined movement patterns  
 
Pain scores 
 
Effects of recumbence  
 
Effects of prolonged standing 
 
Health questionnaires (RMDQ, EQ5D, 
MYMOP) 
 
>50% reduction in VAS post injection 
was considered a successful response 
Regular compression combined movement pattern 
demonstrated 80% sensitivity (95% CI 71% to 89%) and 50% 
specificity (28% to 71%)  - 74% accurate prediction positive 
response to MBB 
 
Strong correlation between pre and post injection VAS scores 
(higher pain correlates to greater reduction in pain post MBB)  
 
Pain not relieved by flexion/recumbence with a regular 
compression pattern demonstrated greatest median 
reduction in post MBB VAS scores  
 
No association between MBB response and  
RMDQ 
EQ-5D 
MYMOP 
Duration of symptoms  
Standing as pain provoking activity  
 
Wong & 
Johnson 20127 
N/A  Narrative review  Lower quadrant test of lumbar spinal 
joint motion. 
Extension with side-bending 
and rotation to the same side  
Ipsilateral axial pain suggests facet joint  compression  
Physiotherapy 
texts  
Segmental palpation examining relative hyper and hypomobility  
Passive Physiological Intervertebral Movements (PPIVMs)  
Passive accessory Intervertebral Movements (PAIVMs)  
Combined movements  patterns  
Palpation of local tenderness with somatic referral pattern  
Seminal 
osteopathic 
texts  
Emphasis on palpation 
Consideration of segmental and general spinal mechanics 
Palpation of tissue tension/texture 
Mobility restriction/’end feel’ idea of ‘low back strain’ 
Palpation of local tenderness  
Emphasis on ’locking’ defined as a ’blocking hypomobility’  
Emphasis on seated and standing examination based on Fryette spinal mechanics. 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  14 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
6 Injection of facet joints 
 
6.1 Summary 
 
Question: What is the agreed technique for the injection of facet joints? 
 
Any research project that investigates facet joint injection must define the technique for injection.  
 
What the evidence suggests 
Key educational/instructional texts for facet joint injection describe details of each author’s technique. 
A broad methodology emerges that varies in detail within a narrow range of options.  
 
Implications for the study 
For this study we need to achieve a single, detailed process for therapeutic injection of lumbar facet 
joints that is acceptable to the professional community, and can be applied consistently across all 
participating study centres. 
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6.2 Background 
 
While many have reported their individual techniques for the therapeutic injection of lumbar facet 
joints there is little consensus and no guidelines or recommendations for current best practice. The 
purpose of our review is to: Report the evidence on the techniques, practices and processes 
recommended and used in current clinical practice to administer fluoroscopically guided therapeutic 
facet joint injections to patients with facetogenic low back pain. 
 
To help in identifying the important issues and to facilitate the process of seeking consensus, the study 
team deconstructed the procedure of injection into a number of key topics and these form the basis 
of the review.  
The key topics and the rationale for their inclusion are shown below. 
Topic Rationale 
 
1: Pre-injection consent/risk 
management procedures 
 
To seek consensus on pre injection consent/risk management 
procedures. 
 
2: Processes used to select the 
facet joint(s) to be injected 
 
To seek consensus on the procedures used by clinicians to 
determine the appropriate facet joint(s) to be injected 
(location/level, single/multiple joints, unilateral/bilateral 
injections). 
 
3: Identification and visualisation 
of the selected joints 
 
To seek consensus on the procedures used by clinicians to ensure 
the accurate positioning of the needle in the joint cleft. 
 
4: Positioning of patient 
 
To seek consensus on the positioning of the patient to ensure 
optimal access to the lumbar facet joints.  
 
5: Skin cleansing/sterilisation 
methods/materials 
 
To seek consensus on the skin cleansing/sterilisation methods 
and materials used by clinicians, balancing sterilisation, 
contamination and neurotoxicity issues. 
 
6: Administration of local 
anaesthetic/composition  
 
To seek consensus on the methods and materials used by 
clinicians to numb the skin. 
7: Gauge/type/length of needle 
 
To seek consensus on the needle gauge, length and point type.  
 
8: Method of approach to the joint 
 
To seek consensus on the procedures used by clinicians in 
selecting the joint injection site (inferior or superior recess/pole). 
 
9: Methods used to confirm intra-
articular positioning of needle 
 
To seek consensus on the procedures used by clinicians to 
confirm intra-articular positioning of needle (clinician feel, X-ray 
parallax, use of contrast medium). 
 
10: Dose of radiation used to 
visualise the joint 
 
To seek consensus on the dose of radiation used to visualise the 
joint while minimizing X-ray exposure. 
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6.3 Methods  
 
Search strategy: An extensive search of PubMed and EMBASE (January-March 2014) was conducted 
and a wide ranging search of key instructional texts was undertaken. 
The search strategy consisted of the following. 
Target condition search terms. (All title and abstract) 
 Low back pain 
 Back pain 
 Spinal pain 
 Spinal diseases 
 Facet 
 Facet joint 
 Zygapophysial  joint 
 Lumbar sacral pain 
 Facetogenic pain 
 Spinal pain 
 Facet syndrome 
 Paravertebral facet pain 
 
Intervention search terms. (All title and abstract) 
 Intra-articular facet injection(s) 
 Image guided injection(s) 
 Interventional spinal procedure(s) 
 Fluoroscopic/fluoroscopy 
 Diagnostic 
 Therapeutic 
 Injection 
 Percutaneous 
 Spinal intervention 
 Procedure 
 
11: Optimal type/configuration of 
X-ray machine/equipment etc. 
 
To seek consensus on the optimal type/configuration of X-ray 
machine/equipment.  
12: Injectate volume 
 
To seek consensus on the injectate volume. 
13: Injectate composition 
 
To seek consensus on the composition of the injectate (local 
anaesthetic/steroid mix). 
 
14: After care advice 
 
To seek consensus on after care advice (in accordance with the 
current practise of the participating local institution). 
15: Other 
 
To seek consensus on other issues not included in other topics. 
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Publication type search terms. (All title and abstract) 
 Conference 
 Consensus development  
 Clinico-pathological Congress 
 Convention 
 Guideline(s) 
 Recommendation(s) 
 Clinical 
 Best Practice(s) 
 
Inclusion criteria: 
 Guidelines 
 Recommendations 
 Therapeutic 
 Intra-articular injection 
 Lumbar facet joint 
 Flouroscopy 
 
Exclusion criteria: 
 Diagnostic 
 Medial branch block 
 Thoracic, cervical facet joint 
 Peri-articular 
 CT guided 
 MRI guided 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  18 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
6.4 Results 
 
 
 
 
 
 
 
 
 
Review Process: Injection of facet joints 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  19 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
Topic 1: Pre-injection consent/risk management procedures 
Reference Data Comments* 
Renfrew DL 20049 Informed consent issues may be divided into 3 topics: 
description of the procedure/possible drug side 
effects/delineation of material risks. 
The patient to be given a precise description of the 
procedure, warnings about drug side effects and of 
material risks. Information about alternative 
procedures is also given.   
 
Patients should be warned that injections may 
recreate or exacerbate their pain. Local anaesthetic 
may cause numbness. A review of corticosteroid side 
effects (eg changes in mood/appetite/insomnia 
/sweating/hot flushes/rash/gastrointestinal upset). 
 
 
Deer TD 200410  
 
Contraindications: 
Absolute: Major hypersensitivity to anaesthetic 
solutions or glucocorticoids 
Local infection at site of proposed injection 
Active infections (glucocorticoids suppression of 
immunity). 
Contra indications to glucocorticoids. 
Informed consent should include awareness of 
possible: 
Temporary anaesthesia, regional or referred 
secondary to anaesthetic effect. 
Insomnia for ½ nights post procedure. 
Facial flushing/truncal rash. 
Low grade fever 1/3 days post procedure 
Heartburn, stomach pain, nausea for ½ days post 
procedure 
Mild to moderate headache secondary to 
glucocorticoid side effects. 
 
 
Dreyfuss PH et al 
200311 
 
 
 
 
 
Contraindications to z-joint injection include bleeding 
diathesis, those on anticoagulants including 
antiplatelet agents, local or systemic infection or 
spinal malignancy. Z-joint injections should not be 
commonly employed in patients who have new 
neurological impairment of spinal origin as 
determined by dermatomal sensory loss, true muscle 
weakness and definite neural tension signs. 
 
 
Ackerman WE et al 
200812 
The patients continued their medications previously 
prescribed for medical reasons such as diabetes, 
hypertension, asthma, etc. throughout this study. 
Opioids, nonsteroidal anti-inflammatory drugs, and 
muscle relaxants prescribed by referring physicians 
were discontinued 14 days before the injection. 
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Schutz P et al 201113 Patients fulfilling criteria underwent radiological 
imaging: all had standard X-rays of lumbar spine in 2 
planes, 91.7% had MRI of lumbar spine and 8.3% a CT 
scan, also.  
Refers to 
intraarticular 
facet joint block 
with local 
anaesthetic as a 
diagnostic tool to 
specify indication 
of lumbar spine 
surgery 
 
Manchikanti L et al 
2009 A 
Complications: infection, intraarterial or intravenous 
injection, spinal anaesthesia, chemical meningitis, 
neural trauma, spinal cord injury, dural puncture, 
pneumothorax, radiation exposure, facet capsule 
rupture, haematoma formation, and steroid side 
effects. 
 
Peh WGC 201114 The patient comes fasting for 6 to 8 hours prior to the 
procedure. 
 
*comments column in all the tables in section six contains items that the study team considered 
important to take into account when assessing the data. 
Topic 2: Processes used to select the facet joint(s) to be injected 
Reference Data Comments 
Deer TD 200410 Facet levels to be injected should be correlated to 
patient completed pain drawings 
 
Shih C et al 200115 The lumbar zygapophyseal joint was matched to the 
patient’s subjective orientation of symptoms, 
according to the mapping of pain-referral patterns in 
symptomatic patients by Mooney and Robertson. 
Bilateral zygapophyseal joint injections were related 
to patient self-complaints of pain.  
If position was ambiguous, the 2 contiguous joints 
were injected. 
Plain X-ray films of the lumbar spine were reviewed to 
determine the exact lumbar level of injections, and to 
ensure there was no vertebral bone disease. 
 
Ackerman WE et al 
200812 
MRI imaging and SPECT scans were used to identify 
facet joint pathology and positive lumbar facet.  
 
Destouet JM et al 
198216 
Only one level injected per study to determine which 
joint were symptomatic  
 
Based primarily on clinical evidence, especially focal 
tenderness over joint(s).  
 
  
 
Rados I et al 201317 If no localised signs are evident, recommended sites = 
L4-L5 and L5-S1 facet joints (ipsilateral for unilateral 
back pain or bilateral for bilateral pain) 
 
Schutz P et al 201113 Segment which was clinically or radiogically most 
likely affected was chosen.  And if indication not 
Refers to 
intraarticular 
facet joint block 
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Topic 3: Identification and visualisation of the selected joints. 
Reference Data Comments 
O’Connor T et al 
200319 
C-arm fluoroscopy is positioned at an angle of about 
30o, tilted towards the side of the joint to be injected 
and adjusted until the joint is well visualised. A radio-
opaque object is positioned over the joint and the 
skin marked. 
 
Prithvi Raj P et al 
201225 
Place the C-arm in a posteroanterior position. Identify 
the midpoint of the intervertebral space at the target 
level. Adjust the lower endplate of the target 
vertebral body to be aligned by moving the C-arm in 
cephalocaudal direction.  Turn the C-arm in the 
oblique direction approximately 45o from L4-L5 and 
L5-S2 level, and 30o for upper levels until the facets 
become visible. 
 
Rathmell J 200626 C-arm is rotated obliquely 25-35o from the sagittal 
plane and without caudal angulations.  
This angle allows 
direct 
visualisation of 
the facet joint.  
Waldman SD 200920 Beam is rotated in a saggital plane from an anterior to 
posterior position, which allows identification and 
visualisation of the articular pillars of the respective 
vertebrae and the adjacent facet joints. 
 
Fluoroscopy beam is aimed directly through the 
introducer needle which is repositioned 
fluoroscopically until it points to the inferior aspect of 
the facet joint. 
 
Following bony contact, the spinal needle is 
withdrawn and introducer needle repositioned 
superiorly, aiming toward the facet joint. The spinal 
needle is then re-advanced through the introducer 
needle until it enters the target joint.  
 
 
 
 
An 18-gauge, 1 
inch needle serves 
as an introducer 
and the 25-gauge 
is inserted 
through it. 
possible, the statistically most affected segment L4/5 
was tested. 
 
3.3% injected at level L3/4, 46.7% at L4/5, 50% at 
L5/S1 
 
Bilateral. 
with local 
anaesthetic as a 
diagnostic tool to 
specify indication 
of lumbar spine 
surgery 
Carette S et al 
199118 
Unilateral/bilateral depending on pain on one/both 
sides of spine. 
 
Peh WGC 201114 Pain drawings may be helpful in identifying the 
specific levels that are associated with the patient’s 
complaints. The patient’s medical and imaging records 
should be carefully reviewed, and the magnetic 
resonance (MR) images should be compared with 
radiographs. 
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Schweizer ME 
200727 
Oblique approach: C-arm is started in the posterior-
anterior projection and centred onto the joint of 
interest.  The X-ray tube is rotated towards the lateral 
direction until the first profile of articular margins is 
seen.  
 
Posterior approach: The X-ray tube is left in a vertical 
position centred over the level of interest in order to 
access the inferior recess just below the superior 
articular process.  
The traditional 
45o oblique 
position profiles 
the anterior 
aspect of the 
joint, but 
observation of the 
most posterior 
position of the 
joint is required to 
ensure correct 
targeting.  
 
Often the 
landmarks of the 
superior articular 
process are not 
well visualised. 
Fenton DS et al 
200321  
Beginning from straight AP- C arm is positioned 
obliquely 10-45o until posterior of facet joint appears 
‘open’ 
 
Agorastides ID & 
Kumar N 200122 
C-arm is rotated until the facet joint space is first 
seen. This renders the beam parallel to the 
posterolateral part of the joint, which is accessible for 
direct puncture. 
 
El-Khoury GY et al 
199123 
The posterior aspect of the joint is profiled 
fluoroscopically 
 
Carrera GF et al 
198024 
Computer Tomography (CT) prior to facet block shows 
the lumbar facet joint and can provide additional 
information about facet orientation. 
 
When facet joints are relatively straight and lie almost 
entirely in an oblique plane, they will be seen best 
with the beam oriented in an oblique plan. 
 
Destouet JM et al 
198216 
45o oblique radiograph of the lumbar spine: the 
anterior portion of the joint space is seen and the 
posterolateral portion of the joint is accessible to 
puncture from a posterior approach.  
 
Rados I et al 201317 Beam is rotated obliquely 10o to 40o to get best image 
of joint space 
 
Carette S et al 
199118 
Patient rotated in the oblique position until facet-joint 
space visualised 
 
Peh WGC 201114 The upper lumbar spine may require obliquity of as 
little as 30o, while the lower lumbar spine may require 
obliquity of up to 60o. 
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Topic 4: Positioning of patient 
Reference Data Comments 
O’Connor T et al 
200319 
Prone. Pillow under anterior superior iliac spine.  
Prithvi Raj P et al 
201225 
Prone with a pillow under the abdomen.   
Rathmell J 200626 Prone with the head turned to one side.    
Renfrew DL 20049 Prone with a bolster under the abdomen to flex 
lumbar spine 
 
Waldman SD 200920 Prone position. Pillows placed under the chest to 
allow the lumbar spine to be moderately flexed. 
Forehead allowed to rest on a folded blanket.  
 
Schweizer ME 
200727 
Prone position with pillows or cushions underneath 
the abdomen.  
This is thought to 
reduce lumbar 
lordosis and 
increase the size 
of the inferior 
recess.  
Deer TD 200410 Prone or slightly oblique from prone.  
Fenton DS et al 
200321 
Prone.  
Agorastides ID & 
Kumar N 200122 
Prone on the fluoroscopy table, with a pillow under 
the abdomen. 
 
Shih C et al 200115 Prone position with a pillow under the belly.  
El-Khoury GY et al 
199123 
Most joints can be punctured with the patient either 
prone or in a shallow anterior oblique position, with 
the injected side up. The obliquity should be limited 
to ensure that the most posterior portion of the joint 
is the part in profile. 
 
Carrera GF et al 
198024 
The patient is placed in the prone position. 
If the joint space cannot be seen, the patient is 
rotated into an oblique position with the affected side 
up until a joint space can be identified. 
 
Rados I et al 201317 Prone with pillow under upper abdomen and legs 
slightly abducted. Positioned so that an oblique view 
of lumbar spine is obtained. 
 
Schutz P et al 201113 Oblique prone position.  
Optimal obliqueness: 
 30o for upper lumbar facet joint 
 60o for lower facet joint 
Refers to 
intraarticular 
facet joint block 
with local 
anaesthetic as a 
diagnostic tool to 
specify indication 
of lumbar spine 
surgery 
Carette S et al 
199118 
Prone  
Peh WGC 201114 Prone pillow may be placed below the abdomen to 
generate kyphosis 
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Topic 5: Skin cleansing/sterilisation methods/materials 
Reference Data Comments 
O’Connor T et al 
200319 
The lumbar midline and an area 10cm x 5cm laterally 
is cleaned with antiseptic solution. 
 
Prithvi Raj P et al 
201225 
Area for needle entry is prepared in a sterile fashion.   
Waldman SD 200920 Skin prepared with antiseptic solution   
Fenton DS et al 
200321 
Providone-Iodine (Betadine) and alcohol scrub  
Agorastides ID & 
Kumar N 200122 
The overlying skin is prepared and the C-arm is 
rotated until the facet joint space is first seen. 
 
Shih C et al 200115 Local aseptic and anaesthetic procedures  
Carrera GF et al 
198024 
Sterile skin preparation was done and after that a 
fenestrated sterile drape was placed 
 
Bykowski JL et al. 
201228 
Skin marked, prepped and draped in usual sterile 
fashion 
 
 
Topic 6: Administration of local anaesthetic/composition etc. 
Reference Data Comments 
O’Connor T et al 
200319 
A skin wheal with 1% lidocaine is raised  
Prithvi Raj P et al 
201225 
1% lidocaine for skin infiltration   
Rathmell J 200626 Skin and subcutaneous tissue overlying the facet joint 
are anesthetised with 1-2ml of 1% lidocaine. 
 
Deer TD 200410 Lidocaine 1% plus buffer of 4.2% sodium bicarbonate 
(2:1 lidocaine/Buffer) 
 
Fenton DS et al 
200321 
9.5ml 1% Lidicaine and .5ml 8.4% injectable sodium 
bicarbonate (1m EQ/ML) 
 
Agorastides ID & 
Kumar N 200122 
5–10 ml of 1% lignocaine is injected into the skin and 
subcutaneous tissue (local anaesthetic). 
 
Shih C et al 200115 Local aseptic and anaesthetic procedures  
Ackerman WE et al 
200812 
1mL of 1% lidocaine to anaesthetise the skin. 
 
 
Carrera GF et al 
198024 
Local anaesthesia of the skin after cleaning it.  
Destouet JM et al 
198216 
Skin and subcutaneous tissue infiltrated with 1% 
lidocaine  
 
Rados I et al 201317 Infiltrated local anaesthetic into the skin and deeper 
tissue over the joint 
 
Schutz P et al 201113 Local anaesthetic (and contrast medium) was avoided 
to avoid additional irritation.  
Refers to 
intraarticular 
facet joint block 
with local 
anaesthetic as a 
diagnostic tool to 
specify indication 
of lumbar spine 
surgery 
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Bykowski JL et al 
201228 
Skin and subcutaneous tissue anesthetised with 
lidocaine  
 
Carette S et al 
199118 
Skin infiltrated with 1% lidocaine   
Peh WGC 201114 1% Lignocaine is used for skin infiltration 
The local anaesthetic used here should be 
preservative- free, so as to prevent flocculation of the 
steroid. 
 
 
Topic 7: Gauge/type/length of needle 
Reference Data Comments 
O’Connor T et al 
200319 
25-gauge needle Details of when 
each should be 
used and for what 
purpose was not 
found. 
Prithvi Raj P et al 
201225 
25-guage, 1.5 inch  needle for skin infiltration  
Rathmell J 200626 22-gauge spinal needle   
Renfrew DL 20049 22-gauge spinal needle for most lumbar injections, 
25-gauge for thoracic and cervical injections.  
Selection of 
needle type varies 
with the operator.  
Waldman SD 200920 25-gauge, 2-3.5 inch spinal needle An 18-gauge, 1 
inch needle serves 
as an introducer 
and the 25-gauge 
is inserted 
through it.  
Deer TD 200410 25 gauge (preferred). 22 gauge (largest necessary) 
3.5-5.0 inch most common but possibly 6-7inc 22 
gauge in large patients. 
 
Fenton DS et al 
200321 
22 gauge 3.5 inch Quinke point  
Agorastides ID & 
Kumar N 200122 
21-gauge spinal needle (31/2 or 5 inch) 
 
 
Shih C et al 200115 23-gauge spinal needle  
El-Khoury et al 
199123 
22-gauge spinal needle  
Ackerman WE et al 
200812 
25-gauge 3.5.-inch spinal needle  
Carrera GF et al 
198024 
20 gauge spinal needle  
Destouet JM et al 
198216 
20- or 22-gauge, 3.5 inch spinal needle   
Schutz P et al 201113 22-23-gauge needle, 3.5-5 inches  Refers to 
intraarticular 
facet joint block 
with local 
anaesthetic as a 
diagnostic tool to 
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Topic 8: Method of approach to the joint 
Reference Data Comments 
O’Connor T et al 
200319 
Spinal needle introduced in a vertical direction to the 
skin, until the needle is observed to enter the joint 
space. 
 
Prithvi Raj P et al 
201225 
Advance the needle under fluoroscopic guidance 
toward the inferior aspect of the facet joint to pass 
the inferior subscapular recess.  
 
Rathmell J 200626 Spinal needle is advanced in the axial plane overlying 
the facet joint with 25-35o of oblique angulation from 
the sagittal plane.  
 
Renfrew DL 20049 The needle is inserted along the course of the X-ray 
beam far enough so that it is anchored. Adjust and 
advance until the needle encounters bone, feels as if 
it has entered the joint, or demonstrates a curve in its 
distal aspect. 
 
Target the inferior aspect of the joint.  
 
Posterior approach.  
If an oblique approach, rather than a posterior 
approach, is used, it often works well to target the 
superior or inferior aspect of the joint. 
 
 
Waldman SD 200920 Fluoroscopy beam is aimed directly through the 
introducer needle which is repositioned 
fluoroscopically until it points to the inferior aspect of 
the facet joint. 
 
Schweizer ME 
200727 
Posterior approach: goal is to access the inferior 
recess The needle is placed straight down until the 
bone is encountered. 
 
specify indication 
of lumbar spine 
surgery 
Bykowski JL et al 
201228 
22-gauge, 3.5 inch spinal needle  
Carette S et al 
199118 
22-gauge, 3.5 inch spinal needle  
Peh WGC 201114 23G spinal needle for entering the facet joint 
18G needle for aspirating drugs 
24G  hypodermic  needle  for  skin  infiltration  with 
lignocaine;   
 
The paper states: ‘In thick patients, a longer spinal 
needle may be required. In some  instances,  even  co-
axial  insertion  of  the  spinal needle through an 18 or 
20 G stiff metallic needle (with stillete) may be 
required’.    
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Passage into the joint though the capsule is often 
perceived as loss of resistance or as a “pop”. 
Deer TD 200410 Postero- lateral approach.  
Fenton DS et al 
200321 
Target = posterior recess , most easily entered using 
approach angle of 10-20ofrom AP, but an angle of 30-
45o may be necessary dependent on 
anatomy/osteoarthritis. 
 
Agorastides ID & 
Kumar N 200122 
Using the needle tip as a marker, 5–10ml of 1% 
lignocaine is injected. 
The syringe is disengaged, leaving the needle to 
act as a guide. 
A spinal needle is introduced parallel and close to the 
hypodermic needle, aiming at the inferior recess of 
the joint, until a bony end point is reached. 
In case of difficulty, the superior recess of the joint is 
the second preferred site for needle insertion. 
 
Shih C et al 200115 The zygapophyseal joint was approached posteriorly 
with a 23-gauge spinal needle under fluoroscope. 
 
El-Khoury GY et al 
199123 
The needle is advanced vertically into the joint.  
Carrera GF et al 
198024 
With the beam directed sagitally through the patient, 
or in a minimal oblique position, the most posterior 
portion is demonstrated and can be punctured from 
the back. 
 
The needle is advanced until posterior joint opening is 
contacted. A direct vertical puncture assures that the 
tip will enter the joint space. 
 
Destouet JM et al 
198216 
Spinal needle is directed vertically into the joint space 
until bone or cartilage is reached. 
 
Carette S et al 
199118 
Needle directed vertically into the joint space.   
Peh WGC 201114 Lower pole of the inferior apophyseal process, as this 
is the expected location of the inferior recess of the 
facet joint. The inferior recess is preferentially 
targeted since it is located posteriorly, has no direct 
relation with neural elements, is relatively capacious 
and is easy to enter. 
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Topic 9: Methods used to confirm intra-articular positioning of needle 
Reference Data Comments 
O’Connor T et al 
200319 
Confirmation of intra-articular placement is made by 
observation of the needle tip remaining on the joint 
line as the fluoroscope is rotated laterally.  
 
Correct placement is indicated by outlining the joint 
with 0.5ml of non-ionic radio-contrast medium. 
 
Prithvi Raj P et al 
201225 
0.2ml contrast material e.g. iohexol. Move the C-arm 
laterally to reconfirm the depth of the needle.  
 
Rathmell J 200626 Placing contrast in the joint limits the ability to place 
local anaesthetic and steroid within the joint. 
Nonetheless, intra-articular injection of contrast is 
commonly carried out at the lumbar level. 
 
Renfrew DL 20049 Visualise the joint with an ipsilateral oblique view to 
determine if the needle is in the inferior aspect of the 
joint. 
 
0.1-0.3 ml non-ionic contrast material. 
Any extra-
articular contrast 
material injected 
will quickly 
obscure the joint 
margins and 
prevent 
completion of the 
procedure.  
 
If the contrast 
pattern suggests 
that the injection 
is intrathecal, it 
best to stop the 
procedure as the 
anaesthetic agent 
may result in 
spinal block and 
steroid may result 
in arachnoiditis. 
Waldman SD 200920 Biplanar fluoroscopy and 1ml contrast medium.  
Schweizer ME 
200727 
Small amount (0.5 cc) of contrast material.  
Deer TD 200410 Needle insertion is performed with gentle, small 
incremental advances observing fluoroscopically 
intermittently. 
 
Possible to use 
non-ionic water-
soluble iodinated 
contrast agents 
eg. Iopamidol and 
Iohexol 180-
240mgl/ml 
Fenton DS et al 
200321 
Flouroscope rotated until facet joint appears ‘open’ ( 
optimal needle trajectory) 
The 22 guage needle is advanced through the facet 
joint capsule. ‘A release in the needle advancement is 
usually ‘felt’ by the operator when the joint capsule 
has been penetrated. 
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Agorastides ID & 
Kumar N 200122 
2 ml of 0.5% Bupivacaine is injected for diagnostic 
purposes or 1 ml of 0.5% Bupivacaine and 1 ml of 
Triamcinolone for therapeutic purposes. 
 
Shih C et al 200115 A test dose of iopamidol (Iopamiro® 370, 
Bracco, Italy) was injected to confirm intra-articular 
needle localization. 
 
Dreyfuss PH et al 
200311 
Once joint entry is perceived during intra-articular 
blocks, a small amount (0.2 to 0.3 ml) of contrast 
medium should be instilled to ensure intra-articular 
spread. 
 
El-Khoury et al 
199123 
Position of the needle is checked by injecting 0.5-1 .0 
ml of non-ionic contrast material 
 
Ackerman WE et al 
200812 
Each patient received 0.1 ml of radiopaque contrast 
(isohexol 300) before the local anesthetic steroid 
injection to confirm correct needle tip placement. 
Each injection was done using fluoroscopic needle tip 
guidance. 
 
Carrera GF et al 
198024 
The needle is advanced until posterior joint opening is 
contacted. A direct vertical puncture assures that the 
tip will enter the joint space. 
 
The correct position is confirmed by injecting 0.5 – 1 
ml of methylglucamine diatrizoate (Renografin-60, 
Squibb). 
 
Destouet JM et al 
198216 
Needle tip will move with the facet joint when patient 
is turned into a steep oblique position.  
 
0.5-1.5 ml of contrast material (Conray-60 
[iothalamate maglumine])  
 
Rados I et al 201317 0.3 ml of Radiocontrast to produce a arthrogram and 
rotate the C-arm in a sagittal plane  
 
Bykowski JL et al 
201228 
0.2 ml contrast (iohexol)  
Carette S et al 
199118 
0.2-0.5 ml contrast (Omnipaque)  
Peh WGC 201114 The spinal needle is then inserted vertically through 
this point until it reaches the bone. Once it enters the 
joint, a “giving way” sensation is perceived. Some 
minor manipulation may be needed to get into the 
joint space. 
 
In the majority of cases, anatomical location of the 
needle tip on  fluoroscopic  imaging  is  sufficient  for  
localisation. 
 
The intra-articular location of the needle tip is be 
confirmed by rotating the patient and observing the 
needle tip move together with the facet joint. 300 
mg%  Iohexol  as  the  contrast  agent. 
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Topic 10: Dose of radiation used to visualise the joint 
Reference Data Comments 
 No Data  
 
Topic 11: Optimal type/configuration of X-ray machine etc 
Reference Data Comments 
 No Data  
 
Topic 12: Injectate volume 
Reference Data Comments 
O’Connor T et al 
200319 
A total volume of more than 1 ml may damage the 
joint 
 
Rathmell J 200626 The facet joint holds only limited volume (typically < 
1.5 ml).  
 
Renfrew DL 20049 0.5-1.0 ml of local anaesthetic and 0.5-1.0 ml of 
steroid  
(this volume is 
described as low). 
Waldman SD 200920 Up to 2 ml local anaesthetic with or without steroid  Rapid or forceful 
injection may 
rupture the joint 
capsule 
Deer TD 200410 1-2.00 ml  
Fenton DS et al 
200321 
1-1.5 ml  
Agorastides ID & 
Kumar N 200122 
2 ml of 0.5% Bupivacaine is injected for diagnostic 
purposes or 1 ml of 0.5% Bupivacaine and 1 ml of 
Triamcinolone for therapeutic purposes. 
 
Shih C et al 200115 A 0.8–1.5 mL mixture of lidocaine, betamethasone 
dipropionate (Diprospan®, Schering-Plough, Heist-op-
den-Berg, Belgium) and iopamidol (1:1:0.5) was 
injected into the joint.  
The injected volume depended on the pressure 
sensation of the injected joint. 
 
Slipman CW et al 
200329 
Carette (1991)18: 1 ml of methylprednisolone acetate 
(20mg) combined with 1ml of normal saline 
Lilius (1989)30: Three groups.  
First group 6ml bupivacaine hydrochloride (30mg) and 
2ml methylprednisolone (80mg).  
Second group treated with a pericapsular injection of 
bupivacaine and methylprednisolone.  
Third group 8 ml normal saline intraarticularly.  
Marks (1992)31: 0.5 ml of methylprednisolone acetate 
and 1.5 ml lidocaine1%. 
Lynch and Taylor (1986)32: 60mg of 
methylprednisolone. 
Cited 
studies:18,30,31,32 
 
Lilius et al 
criticised for using 
excessive volume 
Dreyfuss PH et al 
200311 
Maximum volume injected into the z-joints should be 
less than 2 ml, and most authors recommend 
approximately 1.5 ml of total injectate 
 
El-Khoury GY et al 
199123 
In as much as the capacity of the lumbar facet joints is 
only 1 -2 ml, facet joint injections of more than 2 ml 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  31 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
result in leakage of local anaesthetic and 
corticosteroid from the joint. 
Ackerman WE et al 
200812 
The injectate consisted of 0.5 mL of a local anesthetic-
steroid solution (0.5 mL of 1% preservative free 
lidocaine and 0.2 mL (8 mg) of triamcinolone). 
 
 
Carrera GF et al 
198024 
The facet joint is blocked by injecting 2-3 ml of 1% 
lidocaine solution and 10 mg of depo-prednisolone 
acetate suspension. 
 
Boswell MV et al 
200533 
Carette et al (1991): 2 ml 
 
 
Cited study:18 
Rados I et al 201317 1.5 ml (with contrast) 
2 ml (without contrast) 
 
Schutz P et al 201113 1.5 ml. The joint capacity (1-2ml) must not be 
exceeded to avoid extravasation. 
Refers to 
intraarticular facet 
joint block with 
local anaesthetic 
as a diagnostic 
tool to specify 
indication of 
lumbar spine 
surgery 
 
Carette S et al 
199118 
2 ml  
Peh WGC 201114 The volume of the joint usually does not exceed 1.5 to 
2 ml.  We usually terminate the injection when 
resistance is encountered. 
 
 
Topic 13: Injectate composition. 
Reference Data Comments 
O’Connor T et al 
200319 
Lidocaine 1% 0.5 ml plus corticosteroid e.g. 
triamcinolone 25 mg 
 
Rathmell J 200626 A total dose of 80 mg of methylprednisolone acetate 
or equivalent should be divided over all the joints to 
be injected but more than 40 mg per joint is probably 
unnecessary. Using concentrated steroids (40 or 80 
mg per ml) allows 1:1 mixture with local anaesthetic 
(0.5% bupivacaine).  
 
Renfrew DL 20049 Anaesthetic and steroid agents as desired   
Waldman SD 200920 Up to 2ml local anaesthetic with or without steroid 
(80mg of depot-steroid added to first block with 40mg 
added to subsequent blocks) 
 
Deer TD 200410 Marcaine 0.5% or Lidocaine 2% and glucocorticoids:  
Celestone Soluspan (6 mg betamethasone per ml- 
water soluble) 
Depo-Medrol (most commonly used 40 mg/ml 
solution) 
 
NB when multiple 
joint injections 
total 
glucocorticoid 
volumes should be 
limited to; 
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celestone 
Soluspan: 2.5-
3.0ml: depo-
medrol 80-120mg 
Fenton DS et al 
200321 
Short term anaesthetic: 3 ml 2% Lidocaine. 
Long term anaesthetic: 3 ml 5% Bupivacaine 
 
Therapeutic; Combination of 2.5ml Bupivacaine (0.5 
MPF)/,5ml Betamethasone sodium phosphate and 
Betamethasone acetate injectable suspension 6 
Mg/ml 
 
Agorastides ID & 
Kumar N 200122 
2 ml of 0.5% Bupivacaine is injected for diagnostic 
purposes or 1 ml of 0.5% Bupivacaine and 1 ml of 
Triamcinolone for therapeutic purposes. 
 
Shih C et al 200115 A 0.8–1.5 mL mixture of lidocaine, betamethasone 
dipropionate (Diprospan®, Schering-Plough, Heist-op-
den-Berg, Belgium) and iopamidol (1:1:0.5) was 
injected into the joint.  
 
Slipman CW et al 
200329 
Carette (1991) 18: 1 ml of methylprednisolone acetate 
(20mg) combined with 1ml of normal saline 
Lilius (1989)30: Three groups.  
First group 6cc bupivacaine hydrochloride (30mg) and 
21 cc methylprednisolone (80mg).  
Second group treated with a pericapsular injection of 
bupivacaine and methylprednisolone.  
Third group 8 ml normal saline intraarticularly.  
Marks (1992)31: 0.5 ml of methylprednisolone acetate 
and 1.5 ml lidocaine1%. 
Lynch and Taylor (1986)32: 60 mg of 
methylprednisolone. 
Cited 
studies:18,30,31,32 
 
 
Peh WGC 201114 A combination consisting of 1 to 1.5 ml of the steroid 
and local anaesthetic, in equal parts, is injected. 
 
Advisable to follow the recommendation on the upper 
limit of steroid usage (3 mg/kg of body weight of 
steroid, or 210 mg per year in an average person and 
a lifetime dose of 420 mg of steroid, equivalent to 
methylprednisolone) 
 
El-Khoury GY et al 
199123 
3 mg (0.5 ml) of betamethasone and 1 .5 ml of 0.25% 
bupivacaine. 
 
Ackerman WE et al 
200812 
The facet joint is blocked by injecting 2-3 ml of 1% 
lidocaine solution and 10mg of depo-prednisolone 
acetate suspension. 
 
Airaksinen O et al 
200634 
Lilius et al (1989)30: Methylprednisolone and/or 
bupivacaine 
 
Marks et al (1992)31: Methylprednisolone and 
lidocaine 
Cited studies: 30,31 
Boswell MV et al 
200533 
Carette et al (1991)18: 1 ml 20mg of 
methylprednisolone mixed with 1/2 ml of isotonic 
saline 
Cited studies:18, 
35,16,32,36  
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Murtagh (1988)35: 6 mg betamethasone  
 
Destouet et al (1982)16: 1 ml 0.25% bupivacaine and 
40 mg depot methylprednisolone  
 
Lynch and Taylor (1986)32: 60 mg methylprednisolone  
 
Lippitt (1984)36: 1 ml 1% lidocaine and 80 mg depot 
methylprednisolone 
Destouet JM et al 
198216 
1 ml 0.25% bupivacaine hydrochloride and 40 mg of 
methylprednisolone acetate suspension  
 
Rados I et al 201317 Local anesthetic, lidocain or 
bupivacaine/levobupivacain and 20-40 mg of 
methylprednisolone acetate  
 
Schutz P et al 
201113 
Verum: 1.5 ml 1% Mepivacaine  
 
 
Jackson et al (1988)37: 1 ml of 0.5% bupivacaine and 
2mg (0.5ml) of triamcinolone 
Refers to 
intraarticular facet 
joint block with 
local anaesthetic 
as a diagnostic tool 
to specify 
indication of 
lumbar spine 
surgery 
Bykowski JL et al 
201228 
Combined solution of anaesthetic and long acting 
steroid (methylprednisolone, triamcionolon or 
betamethasone).  
 
Carette S et al 
199118 
2 ml 1% lidocaine  
 
1ml (20mg) methylprednisolone acetate mixed with 
1ml isotonic saline OR 2ml isotonic saline.  
 
Staal JB et al 200838 
 
 
 
 
Fuchs et al (2005)39 sodium hyaluronate or 
corticosteroid injection. 
Revel et al (1998)1, lidocaine or saline followed by an 
injection with corticosteroids (i.e. 
cortivazol) near the joints. 
 
Citied studies:39,1 
Boswell MV et al 
200740 
RCT: Fuchs et al (2005)39 
         Carette et al (1991)18 
Observational: 
Schulte et al. steroid, lidocaine and 
5% phenol 
Murtagh et al (1988)35 6 mg 
Betamethasone 
Destouet et al (1982)16: 1 ml 0.25% 
bupivacaine and 40 mg depot 
methylprednisolone 
Lynch and Taylor (1986)32: 60 mg 
methylprednisolone 
Lippitt (1984)36:  1 ml 1% Lidocaine 
and 80mg depot  methylprednisolone 
Cited 
studies:39,18,35,16,32,36
,41 
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Lau (1985)41: Bupivacaine and depot  
methylprednisolone 
 
Boswell MV et al 
200533 
RCT:  Carette et al (1991)18 
Observational:  
 Murtagh et al (1988)35 6 mg 
Betamethasone 
Destouet et al (1982)16: 1 ml 0.25% 
bupivacaine and 40mg depot 
methylprednisolone 
Lynch and Taylor (1986)32: 60 mg 
methylprednisolone 
Lippitt (1984)36: 1 ml 1% Lidocaine 
and 80mg depot  methylprednisolone 
Lau (1985)41. Bupivacaine and depot  
methylprednisolone 
Cited studies: 
18,35,16,32,36,41 
Falco FJ et al 201242 
 
Carette et al (1991)18 
Fuchs et al (2005)39: Hyaluronic acid/glucocorticoid 
Celik et al (2011)43: (Prospective cohort) Diclofnac 
sodium thiocolchicoside ve prilocaine, bupivacaine 
and methylprednisolone 
Anand and Butt (2007)44:local anaesthetic and steroids 
Murtagh et al (1988)35 6 mg Betamethasone 
Destouet et al (1982)16: 1 ml 0.25% bupivacaine and 
40mg depot methylprednisolone 
Lippitt (1984)36: 1 ml 1% Lidocaine and 80mg depot   
 
Cited studies:18, 39, 
43,44,35,16,36 
Peh WGC 201114 40 mg% Triamcinolone (a long- acting steroid depot 
preparation) and 0.5% Bupivacaine (long-acting local 
anaesthetic agent). Mixed in equal volumes. 
 
Henschke 201045 Carette (1991)18: (1ml methylprednisolone acetate 
mixed with 1 ml isotonic saline) 
Lilius (1989)30: (6ml (30mg) bupivacaine hydrochloride 
mixed with 2 ml (80mg) methylprednisolone. 
Cited studies:18,30 
 
Topic 14: After care advice 
Reference Data Comments 
Renfrew DL 20049 Monitor for pain response and record percentage of 
pain relief at 30 minutes. Release patient when stable 
and provide with telephone number to call due to 
incidences of increased pain, numbness or fever, 
swelling or redness. 
 
Deer TD 200410 Post procedure care: 
Wash Iodine scrub from skin, apply band aid over 
puncture. 
Explain possible localised anaesthesia at injection site 
and possible referred pain along course of normal 
pain.  
Explain possible glucocorticoid side effects. 
An information and instruction sheet should be given. 
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Patients to remain 15/20 mins in waiting area and 
report immediate results before final discharge. 
Fenton DS et al 
200321 
Recommends pain diary of patient symptoms 
immediately post procedure and continuing for 5/7 
days. 
 
Ackerman WE et al 
200812 
Patients were prescribed amitriptyline 25 mg at night 
and tizanidine 2 to 4 mg every 8 hours as needed for 
muscle spasms. 
 
Schutz P et al 201113 Pain level was recorded with 10-point visual analogue 
scale before injection and time points after injection 
(30 mins, 60 mins, 2-3 hrs and 6-8 hrs)  
Refers to 
intraarticular 
facet joint block 
with local 
anaesthetic as a 
diagnostic tool to 
specify indication 
of lumbar spine 
surgery 
 
Topic 15: Other 
Reference Data Comments 
 No Data  
 
 
6.5 Current study protocol for facet joint injection 
 
We describe here, as a starting point for discussion, the protocol for injecting facet joints that we have 
proposed to the funders and submitted for ethical approval.   
 
When they attend for injection the operator will make a brief clinical assessment to satisfy themselves 
that facet joint injections are appropriate. Consent for the procedure will be obtained and the current 
pre-injection risk management procedures of the participating study centres will be adhered to. The 
operator will then inject the facet joint(s). We anticipate injecting up to six facet joints in each 
individual (L3/L4, L4/L5; L5/S1) bilaterally. However, where, on clinical assessment, there is unilateral 
pain, or involvement of only some levels the operator may choose to do unilateral injection, or be 
selective on levels injected. We anticipate that everyone should receive at least two injections. This 
pragmatic approach reflects what actually happens in NHS practice. This approach is consistent with 
that used in trials of other complex interventions for low back pain, e.g. manual therapy or a cognitive 
behavioural approach, where practitioners choose from a limited range of options based on their 
clinical assessment of the patient. 
Procedure to position the needle: 
 We do not anticipate using intravenous sedation. 
 Prone position with pillow under abdomen to flatten lumbar lordosis. 
 Intravenous access, resuscitation equipment available. 
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 Skin cleansing with chlorhexidine 0.5% or 2% in alcohol, sterile drapes. (Some clinicians think 
that 2% chlorhexidine is neurotoxic and like to use 0.5% as skin cleansing before nerve blocks. 
On the other hand 2% chlorhexidine is recommended by the control-of-infection experts as 
optimum skin cleansing before intravenous cannulation and may be preferred in some Trusts). 
 X-ray imaging (C-arm fluoroscopy) oblique view to visualise joint. 
 The dose of radiation used will be adequate to visualise the joint while minimizing X-ray 
exposure. 
 Skin weal at needle entry point: 1% lidocaine via 25G hypodermic needle. 
 22G x 3.5 inch (0.7 x 90 mm) needle with Quincke type point guide to joint cleft. 
 Entry to the joint cleft may be indicated by X-ray appearance: observation of the needle tip 
on the joint line with medial/lateral movement of the X-ray beam to cause parallax shift. 
 If entry to the joint has not been achieved after repositioning the needle twice, the needle will 
be positioned on the joint line without further attempts at capsular puncture. 
 Aspiration should be negative for blood or cerebrospinal fluid. 
 We do not anticipate using contrast medium because of the restriction of available joint 
volume and the risk of serious allergic reactions. 
 The immediate post injection advice will be in accordance with the current procedures of the 
participating study centre. 
 
Injection 
 Pre-filled syringes containing bupivacaine 7.5mg and methyl prednisolone 20mg in total 
volume; 2ml will be used for each joint. 
 The full volume, 2ml, will be injected through the spinal needle placed into each joint. Some 
facet joints may not be sufficiently large to take this volume of injectate meaning in practice 
that the injections will be intra- and peri-articular. This reflects what we believe to be current 
practice in the UK. 
 Resistance to injection may occur due to abutment of the needle bevel to a surface or due to 
filling of the intra-articular space: 
o Force should not be used. 
o The needle should first be rotated 90° and a further attempt at injection made. 
o If, after two further 90° rotations resistance to injection persists or if, after successful 
injection of a part volume resistance develops, gentle pressure should be maintained 
on the plunger and the needle withdrawn gradually until resistance to injection falls. 
 After completion of the injection the needle is removed and a sterile dressing applied. 
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7 Interpreting between group differences in score: what is a ‘meaningful 
difference’ between treatment groups at 3-months? 
 
7.1 Summary  
 
Main Question: What is the difference in magnitude of response between treatment and control 
groups that should be considered large enough to establish the scientific or therapeutic importance 
of the results?  
 
Further Questions:  
1.0 What is the minimal between-group difference in change scores necessary for Facet Joint 
Injection(s) to be considered worthwhile? 
1.1 At 3-months, should we be seeking a mean between-group difference in change scores 
that is smaller / the same / or larger than that observed for the trials of manual 
therapy? 
1.2 Informed by the MID-units calculated for the trials of manual therapy (supporting 
evidence), at 3-months should we be seeking a small (<0.5), medium (0.5-1.0) or large 
(>1.0) MID-unit as proof of important difference?  
 
2.0 What magnitude of reduction in pain after the injection constitutes immediate pain relief?  
 
3.0 What proportion of those we inject should obtain immediate pain relief, based on the agreed 
definition, for us to conclude we have selected a population likely to benefit from facet joint 
injections? 
 
Score interpretation is essential to understanding the relative importance, meaningfulness or value 
attributed to differences in scores within or between individuals or groups.46, 47, 48 Two aspects of score 
interpretation of relevance to a clinical trial can therefore be described – the first, relates to the 
evaluation of change over time; the second to discrimination between groups. Whilst guidance for the 
interpretation of within person change over time exists for chronic low back pain, reported as the 
minimal important change (MIC) for both the Roland and Morris Disability Questionnaire (RMDQ; 
score change of 5 or 30% improvement from baseline) and the Pain (NRS; score change of 2 or 30% 
improvement from baseline)49, guidance for interpretation of the between-group difference (BGD) 
does not exist. Interpretation of the relative importance of between-group differences is crucial, 
especially when these between group differences are likely to be small, and is the focus of this work-
stream. 
 
What the evidence suggests 
An initial systematic review failed to identify guidance for interpretation of between-group differences 
in change in chronic low-back pain studies. We therefore conducted two further, complementary 
work-streams to generate evidence with which to inform interpretation:  
1) A meta-analysis of large RCTs of therapist delivered interventions for chronic low back pain from 
which we reported:  
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1.1) mean between-group differences at follow-up points; and  
1.2) calculated the Minimal Important Difference-units (MID-units: mean between-group 
difference in score is divided by the known MIC for a measure50, 51 for individual and the 
combined trials at 3 and 12-months;  
2) A further analysis of data from a large UK-trial (UK BEAM52) and reported:  
2.1) mean between-groups differences; and  
2.2) MID-units for the RMDQ and Pain (NRS) at 4-weeks, 3 and 12-months. 
 
Mean between-groups differences in change in score: As expected, the between-groups differences 
in change in scores are considerably lower than the MIC for individual change calculated for the 
RMDQ: ranging 0.8 to 1.87 at 3-months, and 0.8 to 1.30 at 12-months (Table 7.4.2.2). No studies 
included a Pain (NRS) as a primary (or secondary) outcome measure. 
 
MID-units: Larger MID-units were calculated for the RMDQ when utilising the 30% change from 
estimated baseline mean as the denominator in comparison to a score change of 5: these were of a 
moderate size at 3-months (range 0.20 and 0.69; combined 0.49 (0.37 – 0.61)), but smaller at 12-
months (range 0.14 to 0.49; combined 0.34 (0.21-0.48)). Interpretation of effect suggests that active 
treatment may benefit an appreciable number of patients at 3-months, but fewer at 12-months. Small 
to moderate MID-units for the Pain (NRS) were calculated at 4-weeks (0.21), 3-months (0.40) and 12-
months (0.40). Interpretation suggests that few people will achieve important benefits (pain 
reduction) from treatment at 4-weeks. However, the larger MID-units at both 3 and 12-months 
suggest that treatment might result in pain reduction in an appreciable number of patients. 
 
Implications for the study:  
Understanding the relative value of one intervention against another is important. We are seeking to 
describe the size of difference between groups that should be considered sufficiently important, and 
hence have implications for whether we proceed to a main study.   
 
What magnitude of reduction in pain after the injection constitutes immediate pain relief? 
An important aspect of interpreting the findings of the feasibility study is knowing whether we have 
correctly selected people who have facet joint pain.  Whilst we cannot, within this study, do a gold 
standard diagnostic assessment involving placebo and active injections we will be able to assess 
immediate response to their injections.  Immediately prior to the procedure participants will be asked 
to rate their current pain on an 11 point (0-10) numerical rating scale.  We will repeat this 45-60 
minutes after injection.  Those participants who obtain pain relief at this time will be deemed as having 
‘confirmed’ facet joint pain. This group with ‘confirmed’ facet joint will include both those who have 
gained pain relief from the local anaesthetic and placebo responders and exclude those for whom 
injectate was not injected in, or adjacent, to the facet joints. 
 
For our current purpose we need to decide on what is immediate pain relief from the injection.  Do 
we only accept absence of low back pain, or do we accept any minimal level of pain as pain relief, or 
might we define responders as those with a substantial percentage improvement (30%, 50%, 70%).  
What the evidence suggests 
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We are not aware of any robust evidence to inform this decision and are seeking consensus on what 
we should accept as pain relief.  
 
What proportion of those we inject should obtain immediate pain relief, based on the agreed 
definition, for us to conclude we have selected a population likely to benefit from facet joint 
injections? 
This would ideally be 100%; however, the best comparable study of which we are aware achieved 
relief of pain in 62% of subjects. For a pragmatic study of this nature an immediate response rate well 
below 100% would be acceptable and is partly dependent on how effective and safe we consider the 
injections to be.  If, a substantial beneficial effect is expected in selected cases and adverse events are 
minimal then quite a low rate of immediate response could still translate into a worthwhile effect 
across the whole population. 
 
What the evidence suggests 
We are not aware of any robust evidence to inform this decision and are seeking consensus on what 
we should accept as pain relief.  
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7.2 Background 
 
Patient-reported outcome measures (PROMs) are self-completed questionnaires which support 
patients in communicating how they feel, what they can do and how well they live their lives as a 
consequence of their health and associated healthcare. Informed by consensus recommendations46, 
two PROMs have been selected as the primary outcome measures for the FIS trial: 
 Roland and Morris Disability Questionnaire (RMDQ) 53 : a 24-item self-completed 
questionnaire about the impact of back pain on activities of daily life. A binary response is utilised in 
which patients affirm (‘check’) items that have relevance to them ‘today’. ‘Checked’ items receive a 
score of 1; checked items are summed, producing a score range 0-24, where higher scores equate to 
worse functional ability (see appendix 11.1 for copy). 
 Pain – Numerical Rating Scale (Pain-NRS): a single item, 11-point scale on which captures 
pain severity using a 0-10 numerical response scale. Score 0-10 where higher scores equate to most 
severe pain (see appendix 11.2 for copy). 
Interpretation of change in PROM score is essential to understanding the relative importance, 
meaningfulness or value attributed to differences in scores within or between individuals or groups. 
46, 47, 48 Two aspects of score interpretation of relevance to a clinical trial can therefore be described – 
the first, relates to the evaluation of change over time; the second to discrimination between groups:  
1. Minimal important change (MIC):  defined as the smallest difference in score that represents 
an important change within individuals or groups over time. If we are interested in evaluation 
of change, we need to interpret the differences in scores within individuals or groups over 
time which is meaningful. 46, 48 Guidance for interpretation of the MIC for both the RMDQ and 
Pain (NRS) following completion by patients with chronic low back pain exists49: 
RMDQ:   5 (or 30% improvement from baseline) 
 Pain NRS:  2 (or 30% improvement from baseline) 
 
2. Between-group difference (BGD): defined as the difference in magnitude of response 
between treatment and control groups that should be considered large enough to establish 
the scientific or therapeutic importance of the results. 48 Interpretation of the relative 
importance of between group differences is crucial, especially when these between group 
differences are likely to be small. However, guidance for interpretation of the between-
group difference (BGD) in chronic low back pain studies does not exist. 
Of note, criteria for the MIC in individuals over time cannot be extrapolated to the interpretation of 
between-group differences. For example, although a 5-point reduction on the RMDQ can be 
considered a minimally important change for an individual patient, it should not be concluded that a 
5-point difference in mean improvement in functional ability between treatment groups is necessary 
for a treatment benefit to be considered important. Moreover, guidance from the FDA (PRO) suggests 
that meaningful change at an individual level is generally ‘larger than the minimal important difference 
for application to group mean comparisons’. 54 
Minimal Important Difference units (MID-units): Where differences between groups are statistically 
significant, interpretation of the magnitude of effect is important. 55 In the context of pooling results 
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from systematic reviews or meta-analyses of randomised controlled trials, a complementary approach 
to calculation of the standardised mean difference (SMD) has been proposed – the Minimal Important 
Difference unit (MID-unit). 51, 55 The MID-unit is calculated as the mean difference between groups 
divided by the MIC associated with the specific outcome variable. Suggested MID-units interpretation: 
if the pooled estimate is greater than 1 MID-unit, many patients are likely to gain important benefits 
from the treatment; an estimate of effect between 0.5 and 1.0 would suggest that the treatment may 
benefit an appreciable number of patients; an estimate less than 0.5 MID units suggests that it is 
increasingly less likely that an appreciable number of patients will achieve important benefits from 
treatment. 55 
Aim: 
To provide guidance to support interpretation of between-group differences (as defined above) for 
the RMDQ and Pain (NRS) in the chronic low back pain population. 
Main question:  
What is the difference in magnitude of response between treatment and control groups that should 
be considered large enough to establish the scientific or therapeutic importance of the results? 
Further Questions: 
Should we be seeking a smaller or larger MID-unit as proof of important difference?  
What magnitude of reduction in pain after the injection constitutes immediate pain relief? 
 
 
7.3 Methods  
7.3.1 Systematic review of evidence in support of the between-group difference on the RMDQ 
and Pain (NRS) in the chronic low back pain population. 
Search strategy 1 (see appendix 11.3): An extensive search of PubMED and EMBASE (2006-March 
2014) was conducted. The search strategy consisted of the following strings: 
 #1 Instrument search: a) All terms for RMDQ; b) All terms for Pain (NRS). 
 #2 Population search: all terms for low back pain (two separate searches: a or b). 
 #3 Measurement terms of relevance to ‘between-group difference’.56 
 #4 Exclusion filter 
 Searches were: #1 (a or b) AND #2 (a or b) AND #3 NOT #4. 
Search strategy 2: An author specific search was also conducted. 
Inclusion criteria: 
Article: 
 Specific evaluation of the NRS (Pain) and/or the RMDQ for evidence of ‘between-group 
difference’*. 
 Specific to non-inflammatory LBP population only. 
 Anglicised / English translation of the measures only. 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014  42 
The University of Warwick                                                                                                                                                                    
 Version 2.0   
 Completion by Adults (18years and above). 
 Self-completion only (not proxy). 
Measures (PROMs): 
 RMDQ (all variations of reporting). 
 Pain (NRS) (all variations of reporting). 
 
Exclusion criteria: 
Article: 
• Not specific to the evaluation of the NRS (Pain) and/or the RMDQ for evidence of 
‘between-group difference’*. 
• Not specific to non-inflammatory LBP population. 
• Non-Anglicised / non-English publication. 
• Completion by children (18 years and below). 
• Proxy-completion. 
 
7.3.2 Structured review and meta-analysis of data from large trials of physical interventions in 
chronic low back pain to: 
 
 Identify mean between-group differences (raw data) reported for the RMDQ and Pain 
(NRS).48, 57 
 Support calculation of the Minimal Important Difference Units (MID-units) for the RMDQ and 
Pain (NRS). 51, 55 
Inclusion criteria:  
 Large randomised controlled trials (RCTs) of therapist delivered interventions for low 
back pain (>300 patients included in the analysis) identified from the ‘Repository 
Database’ (housed by Warwick CTU). 
 RMDQ and/or Pain (NRS) included as primary or secondary outcome measures. 
 
Data extraction: 
 Mean (SD) between-group difference in scores at i) baseline; and ii) all follow-up points. 
 MIC if calculated. 
 
Data analysis:  
 Report the range of mean between-group differences of change across treatment 
interventions and at time-points. 
 Compare to known MIC for RMDQ and Pain-NRS for chronic low back pain. 
 Conduct meta-analysis of data extracted. 
 Calculate MID-units. 
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7.3.3 Review of raw between-group differences and calculation of MID-units from large UK-trial 
(BEAM trial data52).51, 55  
 
Responder analysis of data from a large UK trial of chronic low back pain (the BEAM trial52). 48 
 Calculation of mean between-group differences for RMDQ and Pain (NRS) with responder 
analysis.48 
 Calculation of MID-units for the RMDQ and Pain (NRS). 51, 55 
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7.4 Results 
7.4.1 Systematic review of evidence in support of the between-group difference on the RMDQ 
and Pain (NRS) in the chronic low back pain population. 
 
Despite the extensive search, no studies were identified that provided guidance regarding 
interpretation of the between-group difference in magnitude of response (PRISMA flowchart58  – 
figure 7.4 A (Pain-NRS) and 7.4 B (RMDQ). 
 
 
 
 
 
7.4 A) Review Process: Between-group difference in 
scores; Numerical Rating Scale (NRS) 
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However, several discussion 46, 47, 48 and methodological 51, 55 papers were identified which suggested 
that alternative strategies could be explored to provide further guidance for interpretation of the BGD 
in this population. Hence, meta-analysis and re-analysis of data to calculate MID-unit in the current 
synthesis. 
 
 
 
 
7.4 B) Review Process: FIS MIC/MID Roland Morris 
Disability Questionnaire (RMDQ) 
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7.4.2 Structured review and meta-analysis of data from large trials of physical interventions in 
chronic low back pain. 
 
7.4.2.1 Mean between-group differences (raw data) reported for the RMDQ and Pain (NRS)  
 
Included studies: Warwick RCT ‘Repository’ is a database of individual patient data from RCTs of 
therapist delivered interventions for back pain. The repository includes data from 19 clinical trials 
totalling 9328 participants. Following application of our inclusion criteria, three out of five short-listed 
large trials (>n=300 patients included in the analysis) of physical therapy interventions in patients with 
chronic low back pain which included the RMDQ and/or Pain (NRS) as primary outcome measures 
were included in the analysis (Table 7.4.2.1). 
 
Table 7.4.2.1 Study characteristics (number of trials n= 3/5 included) 
Author Total trial 
population 
(baseline) 
Mean age (SD) Sex (Female) Primary outcomes 
  Treatment Control  Treatment Control  RMDQ Pain 
(NRS) 
Lamb et al 
(2010) 
(BeST),59, 60 
701 53 (14.6) 54 (14.9) 278 (59%) 142 
(61%) 
Yes No                          
(von 
Korff) 
UK Beam 
(2004)52  
1334 Total pop:  43.0 (11.0) Total pop: 56% female Yes No                          
(von 
Korff) 
Hay et al 
(2005)61 
402 PT – Rx:  
40.9 (11.6) 
Pain Mgt: 
40.4 (12.0) 
110 (55%) 100 
(50%) 
Yes No                       
(VAS) 
 
Raw data: The raw data suggests that differences in mean functional ability (RMDQ scores) between 
control or ‘best care’ groups and a range of physical modalities – CBT with advice, exercise, 
manipulation, manipulation followed by exercise, physical therapy – following 3 months of treatment 
/ follow-up range between 0.861and 1.87 52(Table 7.4.2.2) 
Following 12-months of follow-up the mean between-group difference in RMDQ scores range 0.8 61 
to 1.30 52, 59, 60(Table 7.4.2.2) 
These between-group score differences are considerably lower than the MIC for individual change 
calculated for the RMDQ (score change of 5 or 30% change from baseline). 
No studies included a Pain (NRS) as a primary (or secondary) outcome measure. 
7.4.2.2 Meta-analysis and calculation of the MID-units for the RMDQ.  
 
For all included studies, MID-units were calculated using 1) the recommended MIC of 5 points; and 2) 
the recommended MIC of 30% improvement in score from baseline. MID-units were calculated per 
trial and as an overall score (combined) at 3 and 12-months (Table 7.4.2.3). 
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When calculated using the score change of 5-points, smaller MID-units were calculated for the RMDQ 
at all follow-up points when compared to MID-units calculated using the 30% improvement  from 
baseline as denominator. Using the change in score of 5-points, MID-units for the RMDQ at 3-months 
range between 0.16 and 0.37; the combined MID-unit is 0.28 (0.21 – 0.35). MID-units at 12-months 
are smaller, ranging 0.08 to 0.26; the combined MID-units is 0.20 (0.13 – 0.27). However, when using 
the 30% change in score from baseline, MID-units at 3-months range between 0.20 and 0.69; the 
combined MID-unit is 0.49 (0.37 – 0.61). At 12-months, the MID-units are smaller, ranging 0.14 to 
0.49; the combined MID-unit is 0.34 (0.21-0.48).  
 
Adopting the interpretation recommended by Johnston et al 51, 55, an estimate of less than 0.5 MID-
units suggests that it is increasingly less likely than an appreciable number of patients will achieve 
important benefits in functional ability from treatment. However, an estimate of effect between 0.5 
and 1.0 suggests that treatment may benefit an appreciable number of patients. Larger MID-units 
were reported when the 30% change from baseline score was utilised as the denominator, providing 
more promising results in support of the effectiveness of interventions at improving functional 
ability at 3-months. Smaller MID-units were reported at 12-months. 
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Table 7.4.2.2 Characteristics of included trials of ‘physical treatment’ for b) functional disability (RMDQ) in patients with chronic low back pain 
First 
author 
Intervention ‘Rx’ (n) ‘Ctrl’ 
(n) 
 
Mean 
baseline 
RMDQ 
(SD) 
Mean score Rx group 
at follow-up 
Mean change Rx 
group 
(95% CI) 
Mean score 
Control 
group at 
follow-up 
Mean change 
Control 
(95% CI) 
Mean between-group 
difference in change score 
(95% CI) 
Outcome 
assessme
nt time-
points 
(months) 
 
Lamb et al 
(2010)59,60 
 
Advise plus CBT 
vs ‘best 
practice’ 
355 190 9.0 (SD 
4.7-5.0) 
 2.0 (1.58 – 2.43)  1.1 (0.35 – 1.54) 1.1 (0.38 – 1.71) 3 
393 189   2.5 (1.96 – 3.03)  1.0 (0.40 – 1.67) 1.5 (0.70 – 2.22) 6 
399 199   2.4 (1.89 – 2.84)  1.1 (0.39 – 1.72) 1.3 (0.56 – 2.06) 12 
 
 
 
 
 
 
UKBeam 
(2004)52 
 
 
 
 
 
‘Best care’ in GP 
vs Exercise vs 
Manip vs Manip 
followed by 
exercise 
 
225 
 
287 
 
258 
256                   
(‘best 
care’) 
Total:                
9.0 (4.0) 
(Mean(SE)) 
Exercise: 5.47 (0.29) 
 
Manip: 5.09 (0.28) 
 
Manip+Ex: 4.84 (0.28) 
 
3.5 
 
3.9 
 
4.1 
 
6.83 (0.28) 
 
6.66 (0.30) 
 
6.71 (0.28) 
 
2.1 
 
2.3 
 
2.3 
 
Exercise: 1.36 (0.63–2.10) 
 
Manip:  1.57 (0.82–2.32) 
 
Manip+Ex:  1.87 (1.15–2.60) 
 
 
3 
 
216 
 
273 
 
257 
248  
(‘best 
care’) 
 (Mean(SE)) 
Exercise:  5.74 (0.31) 
 
Manip: 5.15 (0.29) 
 
Manip+Ex: 4.72 (0.29) 
 
3.2 
 
3.8 
 
4.2 
 
6.13 (0.30) 
 
6.16 (0.31) 
 
6.02 (0.30) 
 
2.8 
 
2.8 
 
2.9 
 
Exercise:  0.39(-0.41–1.19) 
 
Manip: 1.01 (0.22–1.81) 
 
Manip+Ex: 1.30 (0.54–2.07) 
 
12 
 
Hay et al 
(2005)61 
 
Physical Rx (PT - 
Rx) vs pain mgt 
prog (control) 
162 157 Rx 13.3 
(4.9);  
Ct 13.8 
(4.8) 
PT – Rx: 5.1 (5.8) PT – Rx: 8.1 (6.0) Pn Mgt:  6.0 
(5.9) 
Pn Mgt:                         
7.8 (6.6) 0.8 (-0.5 – 2.1) 
 
3 
165 164  PT – Rx: 4.4 (5.5) PT – Rx: 8.8 (6.1) Pn Mgt: 
5.2 (5.7) 
Pn Mgt: 
8.8 (6.4) 
0.8 (-0.5 – 2.0)  
12 
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Table 7.4.2.3 Results of the meta-analysis (workstream 2) and data analysis from the BeST trial data (workstream 3): mean between-group difference in 
change score and MID-units for the RMDQ and Pain (NRS). 
 Mean between-group difference in change score 
(95% CI) 
MID units (95% CI) 
(mean change / MIC of 5 points) 
MID units (95% CI) 
(mean change / MIC 30% change from baseline) 
 4-weeks 3-mths 12-mths 4-weeks 3-mths 12-mths 4-wks 3-mths 12-mths 
RMDQ          
Lamb 
(2010)59,60  
 
- 1.1                                  
(0.38 – 1.71) 
 
1.3                              
(0.56 – 2.06) 
- 0.22                            
(0.09-0.35) 
0.26  
(0.11 – 0.41) 
- 0.42  
(0.16 – 0.67) 
0.49  
(0.21 – 0.78) 
UKBeam 
(2004)52 
- Exercise:                      
1.36 (0.63–2.10) 
Manip:                            
1.57 (0.82–2.32) 
Manip+Ex: 
1.87 (1.15–2.60) 
 
Exercise:                      
0.39 (-0.41–
1.19) 
Manip:                           
1.01 (0.22–1.81) 
Manip+Ex: 
1.30 (0.54–2.07) 
- Exercise:   
0.27 (0.13 – 0.42) 
Manip: 
0.31 (0.16 – 0.46) 
Manip+Ex: 
0.37 (0.23 – 0.52) 
Exercise:   
0.08 (-0.08 – 0.24) 
Manip: 
0.20 (0.04 – 0.36) 
Manip+Ex: 
0.26 (0.11 – 0.41) 
- Exercise:   
0.50 (0.23 – 0.77) 
Manip: 
0.58 (0.31 – 0.86) 
Manip+Ex: 
0.69 (0.42 – 0.96) 
Exercise:   
0.14 (-0.15 – 
0.44) 
Manip: 
0.38 (0.08 – 0.67) 
Manip+Ex: 
0.48 (0.20 – 0.76) 
Hay et al 
(2005)61 
- 0.8                                        
(-0.5 – 2.1) 
0.8                                                   
(-0.5 – 2.0) 
- 0.16                                       
(-0.10 – 0.42) 
0.16                                       
(-0.09 – 0.41) 
- 0.20                                       
(-0.12 – 0.52) 
0.20                                     
(-0.11 – 0.50) 
          
Meta-analysis 
(combined) 
- - - - 0.28                   
(0.21-0.35) 
0.20                        
(0.13 - 0.27) 
- 0.49                                 
(0.37 – 0.61) 
0.34                         
(0.21 - 0.48) 
          
Raw data 
(BeST) 
(n= 1169) 
1.0 
(0.45 – 1.50) 
1.5 
(0.94 – 2.15) 
 
1.0 
(0.31 – 1.62) 
 
0.20 
(0.09 – 0.30) 
 
0.31 
(0.12 – 0.43) 
0.25  
(0.08 -0.41) 
0.42 
(0.20, 0.64) 
0.68 
(0.43, 0.93) 
0.48 
(0.20, 0.75) 
          
Pain (NRS)          
Raw data 
(BeST) 
(n= 1126) 
0.43 
(0.12, 0.74) 
0.81 
(0.45,1.17) 
0.50 
(0.12, 0.87) 
0.22 
(0.06, 0.37) 
0.41 
(0.22, 0.59) 
0.25 
(0.06, 0.43) 
 
0.13 
(-0.15, 0.42) 
0.54 
(0.22, 0.86) 
0.41 
(0.06, 0.75) 
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7.4.3 Between-group differences of change and calculation of MID-units from large UK-trial 
 
A responder analysis of raw data from a large UK trial (n= 1169) (the UK BEAM tria52) was conducted. 
Scores for the RMDQ and Pain (NRS) were adjusted for sex, age and scores at baseline (Table 7.4.2.3).  
 
7.4.3.1 Mean between-group differences of change in RMDQ and Pain (NRS) scores (Table 7.4.2.3):  
 
MID-units were calculated for using the MIC change in score (7.4.3.2) and MIC % improvement in 
score from baseline (7.4.3.3). 
 
7.4.3.2 The Minimal Important Difference units (MID-units) were calculated for the RMDQ (using 
a recommended MIC of 5) and the Pain (NRS) (using a recommended MIC of 2).  
 
RMDQ: Small MID-units were calculated for the RMDQ at 4-weeks, 3-months and 12-months from a 
further analysis of raw data generated from the UK BEAM trial: ranging from 0.20 (0.09, 0.30) at 4-
weeks to 0.31 (0.12, 0.43) at 3-months (interpretation as above).  
Pain (NRS):   Small to moderate MID-units for the Pain (NRS) were calculated at 4-weeks (0.21), 3-
months (0.40) and 12-months (0.40). Interpretation of the MID-units suggests that few people will 
achieve important benefits (reductions in pain) from treatment at 4-weeks. However, larger MID-units 
are reported at both 3 and 12-months, suggesting that treatment might result in a reduction in pain 
in an appreciable number of patients at these time-points.  
 
 
7.4.3.3 The Minimal Important Difference units (MID-units) were calculated for the RMDQ (using 
a recommended MIC of 30% improvement from baseline) and the Pain (NRS) (using a 
recommended MIC of 30% improvement from baseline). 
 
RMDQ: Use of the alternative (30% improvement in score) denominator produced larger MID-units 
for the RMDQ at all time-points: the MID-units were moderate (0.42 (0.20, 0.64) at 4-weeks) and 0.48 
(0.20, 0.75) at 1-year, and large at 3-months (0.68 (0.43, 0.93)).  
Pain (NRS): Use of the 30% improvement in score produced small to moderate MID-units for the Pain 
(NRS); ranging 0.13 (-0.15, 0.42) at 4-weeks to 0.54 (0.22, 0.86) at 3-months. 
Use of the MIC - 30% improvement in score from baseline as a denominator produced consistently 
larger MID-units when compared to use of the MIC raw score change. Utilising the MIC (30% 
improvement), the largest MID-unit was produced at 3-months follow-up: interpretation would 
suggest that treatment might result in an improvement in functional ability (RMDQ) and reduction in 
pain (Pain NRS) in an appreciable number of patients at 3-months, and to a lesser extent at 12-months. 
However, fewer people will achieve important benefits from treatment at 4-weeks. 
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8  ‘Best usual care’ package 
 
8.1 Summary 
 
Question: What is the optimal conservative management/ rehabilitation for patients with low back 
pain where facet joints have been identified as a contributing source of symptoms? 
 
The review process comprises of three components; 
1. Systematic review (SRs) for physical therapy for facet joint pain 
2. Systematic review for psychological or cognitive behavioural approaches for patients with low 
back pain delivered by non-psychologists 
3. Narrative evidence synthesis from seminal texts of physical therapy 
 
This review utilised two search strategies in order to narrow down physical therapy management, 
concentrating specifically on treatment/management directed at pain arising from the facet joint and 
a second strategy utilising a broader search terms with psychological components to management of 
back pain in general.    
 
What the evidence suggests: 
Rehabilitation of low back pain has been extensively researched over the last few decades and it is 
now widely accepted that this should comprise of both physical and psychological components. 
   
However evidence for specific rehabilitation where facet joints are suspected or known to be the 
source of pain has received little attention.  Whilst seminal texts within the physical therapy suggest 
techniques or methods of treatment that may be of help, at this time there is no agreement regarding 
what constitutes the best physical therapy management in this patient group. 
 
A greater degree of agreement has emerged regarding the need to integrate psychological 
components and techniques within all back pain management.  There is evidence that some form of 
cognitive behavioural approach aiming to address unhelpful beliefs and barriers to recovery has a 
positive, added effect to physical rehabilitation in isolation. In light of a paucity of empirical evidence 
supporting any specific physical therapy approach in this patient group, an option is to provide a 
toolkit of techniques based on the available evidence for therapists to use on an individual basis. 
 
Implication for the study: 
Providing the best, bespoke rehabilitation for both arms of the study is important in order to provide 
a credible treatment for all patients and provide any added value of facet joint injections.   
 
 
 
 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014 52 
The University of Warwick                                                                                                                                                                    
 Version 2.0 
8.2 Background 
 
Whilst low back pain (LBP) has a high prevalence rate, the cause or source of pain is often unclear or 
unknown.  However, the suspected source of pain, along with clinical reasoning62,63, will often direct 
both medical and conservative management strategies.5 Pain originating from the facet joints is 
thought to be common. However, despite numerous clinical opinion and texts indicating how LBP 
arising from different sources may be managed, at present there is no systematic review identifying 
what evidence based components should be included within the conservative 
management/rehabilitation for patients with LBP where facet joints have been identified as a 
contributing source of symptoms.   
 
It is known that musculoskeletal pain and disability, particularly chronic LBP, is often associated with 
psychological distress64, 65, negative beliefs and fear-avoidance behaviour 66, 67, 68, 69. Correspondingly, 
there is a growing evidence base indicating that that the integration of psychological treatment, 
particularly those based upon cognitive behavioural principles can be efficacious in the management 
of chronic pain.  In planning this review it was therefore deemed important to include both the 
physical and psychological management in order to achieve a comprehensive evidence synthesis.     
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8.3 Methods  
 
Search terms 
Two separate search strategies were used;  
=1 physical therapy components  
=2 psychological components 
The full combination of searches for the two separate search strategies are shown in Table 8.3.1 and 
8.3.2   
 
Table 8.3.1: Search term combinations (Physical therapy) 
1 Problem of interest  Low back pain OR back pain OR lumbar vertebrae OR spine 
OR spinal diseases OR facet* OR facet joint* OR 
zygapophyseal joint* OR lumbar sacral pain 
2 Outcome Pain OR function  
3  #1 AND #2 
4 Intervention  orthopaedic OR manual OR physical OR therapeutic exercise 
OR exercise therapy OR rehabilitation OR physiotherapy  
 
5  #3 AND #4 
 Limitations English language, humans 
* wild card/truncation (search term that begin with the letters preceding the asterisk) 
 
Table 8.3.2: Search term combinations (psychological interventions) 
1 Problem of interest  Low back pain OR back pain OR lumbar vertebrae OR spine 
OR spinal diseases OR facet* OR facet joint* OR 
zygapophyseal joint* OR lumbar sacral pain 
2 Outcome Pain OR Function 
3  #1 AND #2 
4 Intervention  cognitive behavioural approach* OR cognitive behavioural 
principle* OR psychological  approach* OR psychological 
principle* OR self-management OR self help 
5  #3 AND #4 
 Limitations English language, humans 
* wild card/truncation (search term that begin with the letters preceding the asterisk) 
 
Databases searched 
MEDLINE, CINAHL and Allied and contemporary medicine database (AMED).  Citation tracking of 
eligible studies.  Hand searching as appropriate 
Inclusion criteria 
Type of study 
All study types were considered initially then included or excluded in the first stage of selection as 
appropriate.  At the second stage of selection, the full text articles were reviewed to determine 
 
 
 
Facet Injection Study Consensus Conference booklet © 27th June 2014 54 
The University of Warwick                                                                                                                                                                    
 Version 2.0 
whether the study utilised physical therapy or psychological techniques to manage ‘facet joint pain’, 
in relation to physical therapy or back or chronic pain in relation to psychological techniques.  
 
In the interest in being as broad as possible with respect to this evidence synthesis it was decided that 
appropriate systematic reviews, identified by the search strategies, could be included.  
 
Selection of studies 
To be included in the review articles/studies needed to include; 
1. Population  
People with low back pain where facet joints have been identified as a contributing source of 
symptoms and no known or suspected serious pathology for the ‘physical therapy’ review. 
2. Intervention 
Any physical therapy management or cognitive behavioural therapy (CBT) type 
intervention/approaches/techniques (delivered by non-psychologists) used as part of the 
management of patients with low back pain where facet joints have been identified as a 
contributing source of symptoms 
3. Setting 
Any; either primary, secondary or community setting was considered again in order to as 
broad as possible in terms of the literature identified.    
 
In order to supplement the systematic review, hand searching of seminal texts for physical therapy 
(as defined by NICE, 2009) was undertaken.  Key texts in the area of physiotherapy and osteopathy 
were identified through personal experience, consultation with relevant experts and 
correspondence with the relevant governing bodies.  No texts in chiropractic were identified.  A 
summary of guidance is presented in Table 8.4.1.  
Exclusion criteria 
The exclusion filters used for PubMed are shown in Appendix 11.4.  Exclusions for other databases 
were;  
 Non-human  
 Non-English language 
 Radiography  
 Cervical 
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8.4 Results 
 
 
Review Process: Rehabilitation/Best Usual care 
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Table 8.4.1 Data extraction  
Reference Setting Type of study 
and outcome 
(OC) measures 
Study Population Intervention Findings 
BEST 
(Lamb et al, 2007 
and 2010)70,60 
 
Primary 
care 
Multi-centred 
RCT  
 
Primary OC 
RMQ  
MVK 
 
N=701 participants  
 
N=233 to active management 
(AM) 
 
N= 468 to AM+CBA 
 
 
Group delivery of 6–8 patients 
Six weekly sessions of 90 minutes 
 
Cognitive behavioural approach (CBA) 
included: 
(i) education to counter unhelpful beliefs 
about LBP and to highlight the importance 
of appropriate levels of activity; 
(ii) use of cognitive re-structuring 
techniques to counter unhelpful beliefs; 
(iii) training on goal setting, baseline setting, 
and pacing for incrementally increasing 
activities; 
(iv) specific focus on fear avoidance and 
attentional effects on pain; 
(v) techniques for self-management of pain 
especially in flare-ups. 
 
Mean additional improvement 
in the CBA arm over AM = 1.1 
[95% confidence interval(CI) 0.4 
to 1.7], 1.4 (95% CI 0.7 to 2.1) 
and 1.3 (95% CI 0.6 to 2.1) 
change points in the RMQ 
at 3, 6 and 12 months  
IMPACT 
 
(Sowden et al 
2012)71 
 
Primary 
care 
Quality 
improvement 
study of 
subgrouping for 
targeted 
treatment 
(STartBack Tool) 
High risk group (4/5 
psychological risk factors for 
chronicity) and any back-
related physical risk factors 
 
 
Evidence based physical therapy 
management in combination with a 
cognitive-behavioural 
Approach with a specific focus on 
communication skills, careful attention to 
language and collaborative goal 
setting. 
 
Exploration of the impact of LBP using 
structured identification of potential 
obstacles to recovery using stem and leaf 
questions. 
 
Trial currently in progress 
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Reference Setting Type of study 
and outcome 
(OC) measures 
Study Population Intervention Findings 
Manca et al 
(2007)72 
 
(Klaber Moffett JA, 
Jackson DA et al. 
2006 – identified 
through hand 
searching)73 
 
Secondary 
care  
Economic 
evaluation 
conducted 
alongside RCT 
 
Primary OC 
TSK at 6 weeks, 6 
and 12 months 
 
 
Neck pain (NP) and LBP 
Pain of more than 2 week 
duration (70% + LBP chronic) 
 
Total n=315 (n=219 LBP/96 NP) 
 
MA with/out The Back Book 
44.84 (16.17)/45.15 (14.93) yrs  
 
SFA with/out The Back Book 
43.15 (14.40)/43.05 (14.33) yrs 
 
The Solution Finding Approach (SFA); 
A brief physiotherapy intervention based on 
cognitive–behavioural principles.   Patient-
centred  and aims to help patients identify 
reasons for their pain and to provide 
solutions and long-term management 
strategies 
 
McKenzie approach (MA): 
Classification spinal condition and the 
prescription of specific therapeutic 
exercises 
 
Both groups subsequently randomised to either 
receive The Back Book or The Neck Book or not 
receive it 
Over a 12-month period SFA 
lower per patient cost of £-24.4 
(95% CI £-49.6 to £0.789).  
 
The mean difference in QALYs 
between the two groups: -0.020 
(95% CI-0.057 to 0.017); 
favouring those receiving 
McKenzie.  
 
Clinically important 
improvement in RMDQ but no 
statistically significant 
differences except: 
- SFA plus Booklet group 
reported less reliance 
on health professionals 
(MHLC-Powerful 
others) at all time 
points. 
- At 6 months MA group 
showed greater 
improvements in TSK 
scores  
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Reference Setting Type of study 
and outcome 
(OC) measures 
Study Population Intervention Findings 
Moffett et al 
(1999)74 
Community RCT 
 
 
Primary OC 
RMDQ at 6 and 
12 months  
 
Aberdeen Pain 
Scale 
EuroQoL EQ5D 
FABQ 
N= 187 patients (1860 years) 
LBP between 4 weeks to 6 
months' duration. 
 
Exercise and CBA 42.6 (8.62) 
yrs 
Usual care 41.1 (9.21) yrs  
 
Exercise classes including strengthening and 
stretching exercises, relaxation session, and 
brief education on back care using a CBA. 
 
Compared to usual primary care 
management  
 
Eight, one hour sessions over four weeks 
Upto 10 participants in each class. 
Exercise class more clinically 
effective and cost effective. 
 
6 and 12 months exercise class 
showed significantly greater 
improvement in the disability 
questionnaire score 
(mean difference in changes 
1.35, 95% CI 0.13 to 2.57). 
 
 
STartBack 
 
(Hill et al, 2011)75 
(Main et al, 
2012)76 
Primary 
care  
RCT  
 
Clinical & cost-
effectiveness of 
stratified with 
non-stratified 
current best 
practice  
 
Primary OC 
RMDQ at 12 
months 
N=851 patients  
 
Intervention n=568 (IG) 
Control groups n=283 (CG) 
CG; 30 minute physiotherapy assessment  
treatment including advice and exercises 
Option of onward referral to further 
physiotherapy 
 
IV group all assessed with advice, 15-min 
educational video (Get Back Active) and 
given the Back Book.  Allocated to three 
risk-defined groups according to the STarT 
Tool 
- low 
-medium 
- high  
 
Low: clinic session only 
Medium: standardised physiotherapy  
High: psychologically informed 
physiotherapy to address physical 
symptoms and function, and psychosocial 
obstacles to recovery 
Mean changes in RMDQ 
significantly higher in the IV 
than CG at 12 months  
(4·3 [6·4] vs 3·3 [6·2] 
 
At 12 months stratified care 
mean increase in generic health 
benefit (0.039 additional 
QALYs) and cost savings 
(£240.01 vs £274.40) compared 
with the control group 
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Reference Setting Type of study 
and outcome 
(OC) 
measures 
Study Population Intervention Findings 
Woods & 
Asmundson 
(2008)77 
Secondary  RCT 
 
Primary OC:  
 
PDI 
 
Secondary:  
SF-MPQ  
HADS 
TSK 
FABQ 
PASS-20 
PCS 
 
N=44 chronic LBP patients 
 
Age: Mean (SD) 
GA    47.23(12.0) 
GiVE 46.13(11.9) 
WLC 46.12 12.5) 
 
Total 
46.45 (11.9) 
 
Graded activity (GA): 
Graded activity, based upon principles of 
operant conditioning.  Shaping of healthy 
behaviours through positive reinforcement 
of predefined activity quotas  
 
All exercises derived from existing 
physiotherapy treatments for LBP 
Graded activity program individualized 
 
Graded in vivo exposure (GivE): 
educating patients about the cognitive-
behavioural perspective on fear avoidance 
followed by graded activity (GA) 
 
Weighting list control (WLC) 
 
GA & GiVE = Eight 45 minute sessions 
conducted twice-weekly for four weeks 
 
GivE statistically 
significantly greater 
improvement on: TSK, FABQ, 
PASS-20, PCS, HADS, SF-MPQ) 
compared to WLC  
 
GivE statistically 
significantly greater 
improvement on: TSK, FABQ, 
PASS-20, and PSEQ) compared 
to GA 
 
ITT analyses: GivE resulted 
in significant improvements on 
the TSK and PCS compared to 
WLC 
Summary of seminal/key texts  
Physiotherapy   Gapping techniques e.g. rotations, transverse mobilisations aimed at increasing IV foraminal space and relieving pressure on z joints 
Passive Physiological Intervertebral Movements (PPIVMs) into flexion? progressing into low loading extension 
Mulligan techniques:  NAGS, SNAGS and MWMs designed to ‘normalise’ facet joint function 
Postural re-education designed to reduce strain on lumbosacral junction 
 
Passive accessory Intervertebral Movements (PAIVMs) and combined movements  as progression 
Trigger point release and soft tissue/fascia release   
 
Osteopathic   Techniques for the lumbar area including generalised non facet specific soft tissue, fascial, harmonic/oscillatory, functional, articulatory and HVLA 
thrust techniques. 
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Whole body/global treatment emphasis rather than tissue/symptom specific 
Specific techniques: e.g. kneading/articulation/springing 
HVT, low velocity techniques  
Soft tissue, articulatory and specific techniques 
Non-specific,  treatment of spinal lesion aimed at ‘normalisation’ 
Osteopathic Treatment. Including HVLT, MET, Myofascial Release, Cranial, Strain-counter strain, Soft tissue/articulatory, Lymphatic techniques, 
Key: 
RMDQ: Roland and Morris Disability Questionnaire  
MVK: Modified Von Korff 
PDI: Pain Disability Index  
SF-MPQ: McGill Pain Questionnaire – Short Form  
HADS: Hospital Anxiety and Depression Scale  
TSK: Tampa Scale for Kinesiophobia  
FABQ: Fear Avoidance Belief Questionnaire  
PASS-20: Short-form of the Pain Anxiety Symptoms Scale  
PCS: The Pain Catastrophising Scale 
MHLC: Multidimensional Health Locus of Control 
 
The one physical therapy article identified within the search strategy could not be sourced (Dreyer et al, 1999)78  
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8.5 Outline of control intervention: a starting point for discussion 
 
Treatment follows guidance from NICE but tailored to individual patients, to ensure that optimal 
treatment is given and maximise treatment benefit. Patients initially undergo a thorough physical 
assessment based on the principles of Maitland manual therapy.62 Symptomatic levels are identified and 
the severity and nature of the symptoms recorded and used to direct treatment. The physical aspects of 
the programme targets facet joints.  
 
To facilitate early treatment and synchronisation of intervention and control treatments individual rather 
than group treatment are used. 
 
There is evidence that manual therapy has effects on descending inhibition and can produce rapid 
analgesic effects in the short term.79,80,81  There is also small scale work indicating that manual therapy 
followed by specific active exercise in chronic non-specific low back pain produces favourable results 
when compared with de-tuned ultrasound followed by specific active exercises.82 Therefore treatment is 
tailored and an adequate dose is given. The specific level and technique chosen is based on Maitland 
selection of technique principle. 
 
Assessment of motor control can include assessment in all three planes, sagittal, transverse and coronal. 
Individualised home exercise regime can be provided based on the patient presentation and their specific 
motor control strategies/dysfunctions. Treatment focuses on improving the motor control/core stability 
which is automatic in nature as opposed to volitionally controlled. The treatment may be based on a bio-
psychosocial model, integrating with the manual therapy a cognitive behavioural approach (CB) which is 
effective in improving quality of life in patients with non-specific low back pain (NSLBP).83 This could 
include basic principles of cognitive restructuring such as identifying Negative Automatic Thoughts (NATs) 
in relation to physical activity and chronic pain and challenging these with adaptive thoughts. Cognitive 
behavioural approaches include working with the patient to understand that NATs are negative appraisals 
of situations that occur that can then influence mood and behaviour. 84 Patients with NSLBP may have 
reduced physical activity due to fear and thought patterns associated with being physically disabled which 
can lead to general de-conditioning. A graded, progressive approach to activity is suggested with home 
exercises prescribed to ensure an optimal level of activity for each patient. 
 
The treatment could be delivered in a patient centred manner, where patients have the opportunity to 
express concerns and expectations and be actively involved in the sessions. The sessions could include 
motivational interviewing to identify barriers and challenges to engaging in activity, as well as assessment 
of self-efficacy and readiness to change. The therapeutic relationship can be an important component of 
the treatment, creating the right environment to integrate psychological, manual and exercise 
components of this treatment. 
 
Outline of content and structure of control intervention – for discussion 
 
Initial assessment 
Initial assessment of 60 minutes. Assessment includes discussion of expectations, fear avoidance and self-
efficacy to assess any perceived challenges and barriers that patients feel may be preventing them from 
engaging in self-management of chronic pain and to allow subsequent treatment sessions to be tailed to 
individual need. For the intervention group, the facet joint injections are given in the period between this 
first assessment and the first follow-up appointment. 
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Individual sessions 
Five further sessions each of 30-minutes incorporating elements of manual therapy, pacing, motor control 
retraining, therapeutic exercise, soft tissue stretches/release, postural and general advice, goal setting 
and challenging negative thoughts associated with physical activity and chronic low back pain as 
appropriate. 
 
Manual therapy (MT) intervention may include: 
 
 Passive accessory intervertebral movements; either central, unilateral applied to either the 
symptomatic level or the level adjacent depending on the severity and irritability.62 
 Soft tissue release/trigger point release/muscle energy techniques as indicated in order to 
facilitate motor control retraining and effectiveness of manual therapy 85 
 Manipulation treatment as indicated.86, 87, 88  
 Active exercise to increase mobility, improved motor control and core stability, improve overall 
strength and stretch any tight muscle groups. 
 Mobility techniques such as flexion in lying, pelvic tilt, side glides in standing and gym ball 
exercises. 
 Motor control retraining exercises (depending on individual assessments). This may include all 
muscles involved in core stabilising of the spine and also reducing activity in more superficial 
muscles that have been shown to become over active in the presence of LBP.  Treatment focuses 
on retraining the ‘co-activation’ pattern of stabilising muscles such as transversus abdominus and 
lumbar multifidus (LM). This includes retraining of lumbar multifidus as it is innervated by the 
medial branch and becomes inhibited ipsilateral to the pain in chronic back pain conditions.89,90 
There is also evidence that specific retraining of ‘core muscles’  can improve pain and disability in 
some back pain patients. 91, 92, 93, 94 
 Passive stretches. Muscle groups identified during assessment as tight or overactive may be 
stretched within the therapy sessions in order to allow for improved spinal mobility and facilitate 
motor control retraining. Stretches taught as part of the home exercise regime. 
 
Home exercises and advice may include 
 Bespoke exercise programme to compliment face to face sessions.  Prescription to include 
frequency, dose, repetitions and progressions.   
 Advice on positions of ease, strategies to use in event of a ‘flare-up’, and strategies to reduce 
increasing pain e.g. use of pelvic tilt prior to standing after prolonged sitting. 
 
Cognitive approaches may include:  
 Pacing including discussion of what is meant by pacing, relevance of pacing and methods to 
incorporate pacing into daily activities such as pacing by time, pacing by numbers or pacing by 
grading activities. 
 Goal setting, including discussion of setting mutually agreed goals related to functional activities 
as well general daily goals and long term goals. Goals agreed between the physiotherapist and 
patient participant. In line with a CB approach, goals may be based on SMART principles; Specific, 
Measurable, Achievable, Realistic and have a Time frame (a date for competition). 84 
 Challenging negative automatic thoughts (cognitive restructuring) including, working with 
patients to identify particular negative thoughts they may have in relation to physical activity and 
fear avoidance, and helping patients challenge their thoughts and adapt positive coping 
strategies. 
 Homework tasks between each session tailored to each individual and what is discussed during 
the session. For example, using pacing on a particular activity identified by the patient, keeping a 
diary of negative automatic thoughts that may trigger anxieties about movement or exercise and 
pain. 
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9 Priori sub-group analyses  
 
9.1 Summary 
 
Question: Which variable(s) should be used for a priori sub-group analyses in the main trial? 
 
For any analysis of sub-groups to be robust the factors that might predict response to treatment need 
to be pre-defined based either on previous empirical data or grounded in the theory.  For a future 
main trial we would wish to select small number of variables to use in a pre-specified sub-group 
analysis. 
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9.2 Background 
 
The identification of sub-groups of individuals who are likely to gain the greatest benefit from different 
approaches to the treatment of low back pain is an important research priority internationally.  This 
study is predicated on their being a group of people who are likely to benefit from facet joint 
injections.  Part of this consensus meeting is focussed on how this phenotypically defined sub-group 
might be identified.  Neither this feasibility study nor any subsequent main study are set up to identify 
and confirm the validity of the entry criteria by including people for whom facet joint pain is 
considered clinically unlikely.  Such a study might be difficult to justify ethically.  
 
Nevertheless we might anticipate that the effect of facet joint injections may not be homogeneous 
across the entire patient population included in the study. We would like to use the data collected in 
the main study to explore such heterogeneity.  We are interested here in factors that affect the 
effectiveness of the treatment (moderators) we are not interested in factors that predict outcome 
irrespective of treatment used.  These are factors measured before randomisation.  Thus, whether 
obtaining immediate pain relief following injection predicts long term benefit is not part of a 
moderator analysis; rather it is a mediator analysis. 
 
To maintain scientific rigour, we wish to define a small number of a priori factors that may be 
associated with moderation of the effect of facet joint injections so that we can specify sub-group in 
advance of a main trial.  Whilst we could select a long list of candidate variables that might moderate 
the effect of facet joint injections, this presents a hazard of getting a false positive result as a 
consequence of multiple comparisons. For this reason, and to ensure practicality of data collection, 
we need to identify a small number of variables that are of the greatest interest to include in this 
confirmatory analysis.  We may also be able to do exploratory analyses on a wider range of factors.    
 
In order to ensure the feasibility of collecting the required baseline data and to allow us to make an 
initial exploration of heterogeneity in treatment effect we will collect data on factors identified in the 
feasibility study. 
 
9.3 Methods 
 
We are not aware of any studies that have explored treatment moderation in randomised controlled 
trials of facet joint injections. In a review of low back pain studies that reported effect moderation we 
identified candidate variables that might be considered significant at the 20% level.  A 20% level was 
chosen rather than a conventional 5% level to ensure we identified all plausible moderators. Broadly 
speaking these were severity, age, sex, anxiety/depression, treatment expectation, self-efficacy, 
quality of life, back beliefs, educational attainment, heavier work (Tables 9.3.1 – 9.3.4). Whilst derived 
from studies of other interventions these might be worth considering.  There may well be other 
moderators that should be considered that are specific to this population.  Such potential moderators 
could be grounded in clinical reasoning or clinical experience.  In this context these may include 
aspects of pain distribution, pain duration, or aspects of the physical examination. 
 
Overall, we are therefore looking for the consensus group to select a small numbers of factors that we 
should consider for MODERATOR analyses (not analysis of predictors).            
 
The tables below summarise the findings on statistical significance from secondary analyses of four 
large trials who tested for how baseline factors might moderate treatment effects.  Where P-value 
was greater than 0.2 we have, for simplicity reported as not significant. 
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Table 9.3.1. Underwood 201195, secondary analysis of BEST dataset; trial of a cognitive behavioural approach.  Outcomes reported - RMDQ (Roland Morris 
Disability Questionnaire); MVK (Modified Von Korff) equivalent to a Numerical Rating Scale (NRS) 
 
Table 9.3.2. Witt 2006.96  Trial of acupuncture.  Significance of interactions reported in main paper.  Outcome measured using Hannover Functional Ability 
Questionnaire  
Witt 200696 
Acupuncture 
Worse initial back function  
Younger  
>10 years of schooling 
p<0.001  Back function and pain improvement at 3 months with acupuncture treatment 
p<0.001 
p=0.01 
  
Study ID Variables Significant interaction with intervention  
(p-value given or no significant interaction seen (NSI)) 
Underwood 
201195 
 
Cognitive 
behavioural 
approach 
 
Troublesomeness (Very/Extremely –
Moderately) 
 
Age ( ≥54 years – <54 years) 
 
Female – Male 
 
Left Full Time Education (>16 years of age – ≤16 
years of age) 
 
Employed – Not Employed 
 
 
HADS – Anxiety (≥11 – <11) 
 
HADS – Depression (≥11 – <11) 
 
p= 0.190 {(95%CI: -1.01 (-2.52, 0.50)}-RMDQ; p=0.184 {(95%CI: -5.04 (-12.47, 2.40)}-MVK 
pain 
 
p=0.035 {(95%CI: -1.58 (-3.05, -0.12)}-RMDQ 
 
p=0.102 {(95%CI: -1.27 (-2.79, 0.25)}-RMDQ 
 
p=0.098 {(95%CI: 1.29 (-0.24, 2.82)}-RMDQ 
 
 
p=0.011 {(95%CI: 1.89 (0.43, 3.35)}-RMDQ; p=0.181 {(95%CI: 5.01 (-2.33, 12.34)}-MVK pain 
 
p=0.195 {(95%CI: -1.12 (-2.83, 0.58)}-RMDQ 
 
p=0.135 {(95% CI: -2.07 (-4.79, 0.65)}-RMDQ; p=0.051 {(95%CI: -14.58 (-29.19, 0.03)}-MVK 
disability  
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Table 9.3.3. Underwood 2007.97  Secondary analysis of UK BEAM dataset.  Tested manual therapy, group exercise of manual therapy followed by exercise 
(combined treatment.  Outcome report Roland Morris Disability Questionnaire 
Study ID Variables Significant interaction with intervention  
(p-value given or no significant interaction seen (NSI)) 
Underwood 
200797 
 
Manual 
therapy or 
manual 
therapy plus 
exercise 
 3 months for RMDQ 12 months for RMDQ 
  
Quality of life 
 
Treatment  
Helpful 
Very helpful 
 
 
Beliefs 
Quality of life 
Pain/Disability 
 
Treatment  
Helpful 
Very helpful 
Combined treatment 
p=0.174 {(95%CI: -0.1 (-0.26, 1.43)} 
 
 
p= 0.073 {(95%CI: -3.2 (-6.74, 0.30)} 
p=0.192 {(95%CI: -2.2 (-5.49, 1.11)} 
 
Manipulation 
p=0.07 {(95%CI: -0.8 (-1.62, 0.06)} 
p=0.118 {(95%CI: 1.4 (-0.35, 3.07)} 
p=0.176 {(95%CI: -1.9 (-4.61, 0.85)} 
 
 
NSI 
p=0.113 {(95%CI 1.6 (-0.38, 3.60)} 
 
NSI 
 
 
p=0.038 {(95%CI: -3.8 (-7.39, -0.20)} 
p=0.019 {(95%CI: -4.0 (-7.38, -0.67)} 
 
 
NSI 
NSI 
p=0.143 {(95%CI: -2.2 (-5.16, 0.75)} 
 
 
p=0.083 {(95%CI: -0.1 (-0.16,0.01)} 
NSI 
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Table 9.3.4. Sherman 2009.98  Secondary analysis of Cherkin acupuncture trials,  compared two acupuncture regimens and a sham procedure with usual care  
Outcome reported Roland Morris disability Questionnaire 
Study ID Variables Significant interaction with treatment for back related dysfunction (Roland score) 
 (p-value given or No significant interaction seen (NSI)) 
Sherman 
200998 
Acupuncture 
 
 
 
8 weeks 52 weeks 
Individualised 
acupuncture 
 
Standardised 
acupuncture 
Simulated acupuncture Individualised 
acupuncture 
Standardised 
acupuncture 
Simulated 
acupuncture 
Age 
 
Self-efficacy 
 
Baseline Roland 
score 
 
Baseline 
bothersomeness 
score 
 
Heavy lifting 
 
Sedentary 
 
Use of narcotic 
medication 
 
Acupuncture 
expectation (top 
tertile) 
NSI 
 
p=0.04 
 
p<.0001 
 
 
NSI 
 
 
 
p=0.03 
 
NSI 
 
NSI 
 
 
NSI 
p=0.08 
 
NSI 
 
p=0.004 
 
 
p=0.10 
 
 
 
p=0.13 
 
NSI 
 
p=0.04 
 
 
p=0.17 
 
NSI 
 
NSI 
 
p=0.001 
 
 
NSI 
 
 
 
p=0.18 
 
NSI 
 
p=0.19 
 
 
p=0.03 
 
 
NSI 
 
NSI 
 
p=0.07 
 
 
NSI 
 
 
 
p=0.01 
 
p=0.12 
 
NSI 
 
 
NSI 
p=0.15 
 
NSI 
 
p=0.07 
 
 
NSI 
 
 
 
p=0.15 
 
p=0.15 
 
p=0.04 
 
 
p=0.17 
NSI 
 
NSI 
 
NSI 
 
 
NSI 
 
 
 
p=0.04 
 
NSI 
 
p=0.19 
 
 
p=0.03 
 
 Significant interaction with treatment symptom bothersomeness score  
(p-value given or No significant interaction seen (NSI)) 
Age 
 
Self-efficacy 
NSI 
 
p=0.14 
p=0.09 
 
NSI 
p=0.07 
 
NSI 
NSI 
 
NSI 
p=0.15 
 
NSI 
p=0.08 
 
NSI 
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Baseline Roland 
score 
 
Heavy lifting 
 
Light/medium 
lifting 
 
Sedentary 
 
Acupuncture 
expectation (top 
tertile) 
 
p=0.01 
 
 
p=0.05 
 
NSI 
 
 
NSI 
 
p=0.1 
 
 
NSI  
 
 
NSI 
 
P=0.12 
 
 
NSI 
 
NSI  
 
 
p=0.0005 
 
 
NSI 
 
NSI  
 
 
NSI 
 
NSI 
 
p=0.16 
 
 
p=0.02 
 
p=0.12 
 
 
p=0.19 
 
p=0.051 
 
NSI 
 
 
NSI 
 
NSI 
 
 
NSI 
 
NSI 
 
NSI 
 
 
NSI 
 
NSI 
 
 
NSI 
 
p=0.06 
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11 Appendix  
11.1 Roland and Morris Disability Questionnaire (RMDQ) 
This section is about your back pain today.  When your back hurts, you may find it difficult to do 
some of the things you normally do.  This list contains some sentences that people have used to 
describe themselves when they have back pain.  When you read them, you may find that some stand 
out because they describe you today.  As you read the list, think of yourself today.  When you read a 
sentence that describes you today, place a cross in the box beside it.  If the sentence does not describe 
you, then leave the box blank and go on to the next one.  Remember, only place a cross if you are sure 
that it describes you today. 
 
1. I stay at home most of the time because of my back.  .........................................................................  
2. I change positions frequently to try and get my back comfortable.  ....................................................  
3. I walk more slowly than usual because of my back.  ............................................................................  
4. Because of my back, I am not doing any of the jobs that I usually do around the house. ...................  
5. Because of my back, I use a handrail to get upstairs ............................................................................  
6. Because of my back, I lie down to rest more often.  .............................................................................  
7. Because of my back, I have to hold on to something to get out of an easy chair.  ............................  
8. Because of my back, I try to get other people to do things for me.  .....................................................  
9. I get dressed more slowly than usual because of my back.  .................................................................  
10. I only stand up for short periods of time because of my back.  ............................................................  
11. Because of my back, I try not to bend or kneel down.  .........................................................................  
12. I find it difficult to get out of a chair because of my back.  ...................................................................  
13. My back is painful almost all the time.  .................................................................................................  
14. I find it difficult to turn over in bed because of my back.  ....................................................................  
15. My appetite is not very good because of my back pain.  ......................................................................  
16. I have trouble putting on my socks (or stockings) because of the pain in my back.  ............................  
17. I only walk short distances because of my back pain.  ..........................................................................  
18. I sleep less well because of my back.  ...................................................................................................  
19. Because of my back pain, I get dressed with help from someone else.  ..............................................  
20. I sit down for most of the day because of my back.  .............................................................................  
21. I avoid heavy jobs around the house because of my back.  ..................................................................  
22. Because of my back pain, I am more irritable and bad tempered with people than usual.  ................  
23. Because of my back, I go upstairs more slowly than usual.  .................................................................  
24. I stay in bed most of the time because of my back.  .............................................................................  
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11.2 Pain – Numerical Rating Scale (Pain-NRS) 
 
Question: “Please rate on a 0 to 10 scale (0 = no pain, 10 = worst pain) average pain over last 24 
hours.”99 
 
11.3 Search string for between-group difference in scores – RMDQ and Pain (NRS): 
Start Date 2006-present 
 
EMBASE PubMED  
NRS:  
#1(a) Instrument search: All Title and abstract 
“numerical rating scale” OR “NRS”  OR  “numerical pain intensity scale” OR “numerical 
pain rating scale” OR “analogue rating scale”    
#2 Population search: (ie string A OR B) 
STRING A All Title and abstract 
"low back pain"OR"back pain"OR"lumbar vertebrae"OR"spine"OR"spinal 
diseases"OR"facet"OR"facet joint"OR"zygapophyseal joint"OR "zygapophysial 
joint"OR "lumbar sacral pain"  
STRING B  
Mesh: Low back pain Generic pop: (a la Hancock Mindy C) 
Back Pain, Low OR Back Pains, Low OR Low Back Pains OR Pain, Low Back OR Pains 
Low Back OR Lumbago OR Lower Back Pain OR Back Pain, Lower OR Back Pains, Lower  
OR Lower Back Pains OR Pain, Lower Back OR Pains, Lower Back OR Low Back Ache 
OR Ache, Low back OR Aches, Low Back OR Back Ache, Low OR Back Aches, Low OR 
Low Back Aches OR Low Backache OR Backache, Low OR Backaches Low OR Low 
Backaches OR Low Back Pain, Recurrent OR Recurrent Low Back pain OR Low Back 
Pain, Postural OR Postural Low Back Pain OR Low Back Pain, Mechanical OR 
Mechanical Low Back Pain Or Low Back Pain, Posterior Compartment 
#3 MIC related measurement terms: instrumentation[sh] OR methods[sh] OR Validation 
Studies[pt] OR Comparative Study[pt] OR psychometrics[MeSH] OR psychometr*[tiab] OR 
clinimetr*[tw] OR clinometr*[tw] OR “outcome assessment (health care) [MeSH] OR outcome 
assessment[tiab] OR outcome measure*[tw] OR observer variation[MeSH] OR observer 
variation[tiab] OR Health Status Indicators[Mesh]  OR (uncertainty[tiab] AND 
(measurement[tiab] OR measuring[tiab])) OR “standard error of measure-ment”[tiab] OR 
sensitiv*[tiab] OR responsive*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab] OR 
clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab]) AND 
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(change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab]) AND 
(change[tiab] OR difference[tiab])) OR meaningful change [tiab]  
#4 Exclusion filter: (“addresses”[Publication Type] OR “biography”[Publica-tion Type] OR 
“case reports”[Publication Type] OR “comment”[Publication Type] OR “directory”[Publica-
tion Type] OR “editorial”[Publication Type] OR “fest-schrift”[Publication Type] OR 
“interview”[Publication Type] OR “lectures”[Publication Type] OR “legal cases”[Publication 
Type] OR legislation”[Publication Type] OR “letter”[Publication Type] OR “news”[Publi-cation 
Type] OR “newspaper article”[Publication Type] OR “patient education handout”[Publication 
Type] OR “popular works”[Publication Type] OR “congresses”[Publication Type] OR 
“consensus development conference”[Publication Type] OR “consensus development 
conference, nih”[Publication Type] OR “practice guide-line”[Publication Type]) NOT 
(“animals”[MeSH Terms] NOT “humans”[MeSH Terms])  
Searches were:#1 (a) AND #2 (string A OR string B) AND #3 NOT #4  
RMDQ: 
All as NRS except instrument search was for RMDQ (#1b) shown below. 
RMDQ 
#1 (b) Instrument search  
“Roland and Morris Disability Questionnaire” OR  “R M D Q” OR  “R M Q” OR “Roland 
Morris Disability Questionnaire” OR  “Roland Morris Disability Scale” OR “Roland & 
Morris Disability Questionnaire”  OR  “Roland Morris Questionnaire” OR  “Roland-
Morris Disability Questionnaire” OR “Roland-Morris Questionnaire”  OR “Roland-
Morris”  OR “ Roland Morris 18 item Disability Questionnaire” OR “Roland-Morris 
Disability” OR “Roland and Morris”  
Searches were:#1 (b) AND #2 (string A OR string B) AND #3 NOT #4  
 
11.4 Exclusion filter for PubMed used in search strategy for ‘Best usual care’ 
 
 (“addresses”[Publication Type] OR “biography”[Publication Type] OR “case reports”[Publication 
Type] OR “comment”[Publication Type] OR “directory”[Publication Type] OR “editorial”[Publication 
Type] OR “fest-schrift”[Publication Type] OR “interview”[Publication Type] OR “lectures”[Publication 
Type] OR “legal cases”[Publication Type] OR “legislation”[Publication Type] OR “letter”[Publication 
Type] OR “news”[Publication Type] OR “newspaper article”[Publication Type] OR “patient education 
handout”[Publication Type] OR “popular works”[Publication Type] OR “congresses”[Publication Type] 
OR “consensus development conference”[Publication Type] OR “consensus development conference, 
nih”[Publication Type] OR “practice guide-line”[Publication Type]) NOT (“animals”[MeSH Terms] NOT 
“humans”[MeSH Terms]) 
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